AU2006200921A1 - Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors - Google Patents

Description

S&FRef: 596625D1

AUSTRALIA

PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT Name and Address of Applicant Actual Inventor(s): Address for Service: Invention Title: Board of Trustees of the University of Illinois, of 352 Henry Administration Building 506 South Wright Street, Urbana, Illinois, 61801, United States of America Bey-Dih Chang Igor B. Roninson Spruson Ferguson St Martins Tower Level 31 Market Street Sydney NSW 2000 (CCN 3710000177) Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5845c REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING EXPRESSION OF GENES REGULATED BY CDK

INHIBITORS

1. Field Of The Invention s This invention is related to cellular senescence and changes in cellular gene expression that accompany senescence. In particular, the invention is related to the identification of genes the expression of which is modulated by a class of cellular gene products termed cyclin dependent kinase (CDK) inhibitors, induced in cells at the onset of senescence. More specifically, the invention provides markers of cellular senescence that are genes whose expression in induced or repressed by such CDK inhibitors The invention provides methods for identifying compounds that inhibit or potentiate cellular senescence by detecting inhibition of repression or induction of these marker genes.

Also provided are reagents that are recombinant mammalian cells containing recombinant expression constructs encoding two different cellular CDK inhibitors, p21 and p16 that are experimentally-inducible, and recombinant mammalian cells containing a recombinant expression construct that expresses a reporter gene under the transcriptional control of a promoter for a gene that is regulated by CDK inhibitors.

2. Summary Of The Related Art Cell cycle progression is regulated to a large extent by a set of serine/threonine kinases, known as cyclin-dependent kinases (CDKs). A special group of proteins, known as CDK inhibitors, interact with and inhibit CDKs, thus causing cell cycle arrest in a variety of physiological situations (see Sielecki et al., 2000, J. Med. Chem. 43: 1-18 and -1references therein). There are two families ofCDK inhibitors. The first one, known as Cip/Kip, includes p 2 1 wan/Ci"" di, p 2 7 Ki p and p 5 7 Ki 2 The second family, Ink4, includes p16I'k4A, p 14 ARF, pl51nk4, pi 1 8 Sk4 c and pl9" k4d Expression of specific CDK inhibitors is activated by different factors. For example, contact inhibition induces p27 and p16 (Dietrich et al., 1997, Oncogene 15: 2743-2747), extracellular anti-mitogenic factors such as TGFp induce p15 (Reynisdottir et al., 1995, Genes Dev. 9:1831-1845), serum starvation induces p27 (Polyak et al., 1994, Genes Dev. 8: 9-22), and UV radiation induces pl6 (Wang et al., 1996, Cancer Res. 56: 2510-2514). In addition, all of the above treatments, as well as different forms of DNA damage induce p 2 1, the most pleiotropic of the known CDK inhibitors (Dotto, 2000, BBA Rev. Cancer 1471: M43- M56).

Of special importance to the field of this invention, two of the CDK inhibitors, p21 and p 1 6, have been intimately associated with the process of senescence in mammalian cells. At the onset of replicative senescence (Alcorta et al., 1996, Proc. Natl.

Acad. Sci. USA 93:13742-13747) and damage-induced accelerated senescence (Robles Adami, 1998, Oncogene 16: 1113-1123), p21 induction results in cell growth arrest.

This surge of p21 expression is transient, however, and is followed by stable activation of p16, which is believed to be responsible for the maintenance of growth arrest in senescent cells. The knockout of p21 (Brown et al., 1997, Science 277: 831-834) orp 16 (Serrano et al., 1996, Cell 85: 27-37) delays or prevents the onset of senescence.

Furthermore, ectopic overexpression of either p21 or p16 induces growth arrest accompanied by phenotypic markers of senescence in both normal and tumor cells (Vogt et al., 1998, Cell Growth Differ. 9: 139-146; McConnell et al., 1998, Curr. Biol. 8: 351- 354; Fang et al., 1999, Oncogene 18: 2789-2797).

p21 has been independently identified by several groups as a protein that binds and inhibits cyclin-dependent kinases (CDK) (Harper et al., 1993, Cell 75:.805-816), as a gene upregulated by wild-type p53 (el-Deiry et al., 1993, Cancer Res. 55: 2910-2919), and as a growth-inhibitory gene overexpressed in senescent fibroblasts (Noda et al., CK 5 1994, Exp. Cell. Res. 211: 90-98). Because of its pivotal role in p53-regulated growth Sarrest, p21 is usually regarded as a tumor suppressor. Nevertheless, p21 mutations in human cancer are rare (Hall Peters, 1996, Adv. Cancer Res. 68: 67-108), and p21 C knockout mice develop normally and do not show an increased rate of tumorigenesis (Deng et al., 1995, Cell 82: 675-684).

Cellular levels of p21 are increased in response to a variety of stimuli, including DNA-damaging and differentiating agents. Some of these responses are mediated through transcriptional activation of the p21 gene by p53, but p21 is also regulated by a variety of p53-independent factors (reviewed in Gartel Tyner, 1999, Exp. Cell Res.

227: 171-181).

Transient induction of p21 mediates different forms of damage-induced growth arrest, including transient arrest that allows cell to repair DNA damage, as well as permanent growth arrest (also termed "accelerated senescence"), which is induced in normal fibroblasts (DiLeonardo et al., 1994, Genes Develop. 8: 2540-2551; Robles Adami, 1998, Oncogene 16: 1113-1123) and tumor cells (Chang et al., 1999, Cancer Res. 59: 3761-3767) by DNA damage or introduction of oncogenic RAS (Serrano et al., 1997, Cell 88: 593-602). A surge of p21 expression also coincides with the onset of terminal growth arrest during replicative senescence of aging fibroblasts (Noda et al., 1994, ibid.; Alcorta et al., 1996, Proc. Natl. Acad. Sci USA 93:13742-13747; Stein et al., 1999, Mol. Cell. Biol. 19: 2109-2117) and terminal differentiation of postmitotic cells -3- (El-Deiry et al., 1995, ibid.; Gartel et al., 1996, Exp. Cell Res. 246: 280-289).

While p21 is not a transcription factor per se, it has indirect effects on gene expression that may play a role in its cellular functions (Dotto, 2000, BBA Rev. Cancer 1471 :M43-M56 and references therein). One of the consequences of CDK inhibition by p21 is dephosphorylation of Rb, which in turn inhibits E2F transcription factors that regulate many genes involved in DNA replication and cell cycle progression (Nevins, 1998, Cell Growth Differ. 9: 585-593). A comparison of p21-expressing cells (p 2 1 and p21-nonexpressing cells (p 2 1 has implicated p21 in radiation-induced inhibition of several genes involved in cell cycle progression (de Toledo el al., 1998, Cell Growth Differ. 9: 887-896). Another result of CDK inhibition by p21 is stimulation of transcription cofactor p300 that augments NFicB (Perkins et al., 1988, Science 275: 523- 527). Activation of histone acetyltransferase p300, that enhances many inducible transcription factors, may have a pleiotropic effect on gene expression (Snowden Perkins, 1988, Biochem. Pharmacol. 55: 1947-1954). p 2 1 may also affect gene expression through its interactions with many transcriptional regulators and coregulators other than CDK, such as JNK kinases apoptosis signal-regulating kinase 1 Myc and others (Dotto, 2000, BBA Rev. Cancer 1471 :M43-M56). These interactions may affect the expression of genes regulated by the corresponding pathways.

Another CDK inhibitor of particular relevance to the present invention is pl6NK 4 A; the human protein has been described by Serrano et al. (1993, Nature 366: 704-707). As mentioned above, p16 is an essential regulator of senescence in mammalian cells. It is also a bona fide tumor suppressor and one of the most commonly mutated genes in human cancers (Hall Peters, 1996, Adv. Cancer Res. 68: 67-108).

p 6 is known to directly inhibit CDK4 and CDK6, and may indirectly inhibit CDK2 as -4well (McConnell et al., 1999, Molec. Cell. Biol. 19: 1981-1989).

There remains a need in this art to identify genes whose expression is modulated by induction of CDK inhibitor genes such as p21 and p16. There is also a need in this art to develop targets for assessing the effects of compounds on cellular senescence, carcinogenesis and age-related diseases.

Summary of the Invention This invention provides reagents and methods for identifying genes whose expression is modulated by induction of CDK inhibitor gene expression. The invention also provides reagents and methods for identifying compounds that inhibit or potentiate the effects of CDK inhibitors such as p21 and p16 on cellular gene expression, as a first step in rational drug design for preventing cellular senescence, carcinogenesis and agerelated diseases or for increasing the efficacy of anticancer therapies.

In a first aspect, the invention provides a mammalian cell containing an inducible CDK inhibitor gene. In preferred embodiments, the CDK inhibitor gene encodes p21 or p 16 In preferred embodiments, the mammalian cell is a recombinant mammalian cell comprising a recombinant expression construct encoding an inducible p21 gene or an inducible p16 gene. More preferably, the construct comprises a nucleotide sequence encoding p21, most preferably human p21, under the transcriptional control of an inducible promoter. In additional, more preferred embodiments, the construct comprises a nucleotide sequence encoding p16, most preferably human p16, under the transcriptional control of an inducible promoter. In alternative embodiments, the construct comprises a nucleotide sequence encoding the amino-terminal portion of p21 comprising the CDK binding domain, more preferably comprising amino acids 1 through 78 of the p21 amino acid sequence. In preferred embodiments, the inducible promoter can be induced by contacting the cells with an inducing agent, most preferably a physiologically-neutral inducing agent, that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter. In a preferred embodiment, the mammalian cell is a fibrosarcoma cell.

In another embodiment of the first aspect of the invention are provided recombinant mammalian cells comprising a recombinant expression construct in which a reporter gene is under the transcriptional control of a promoter derived from a cellular gene whose expression is modulated by a CDK inhibitor, most preferably p21 or p 16. In a preferred embodiment, the promoter is derived from a cellular gene whose expression is repressed by a CDK inhibitor such as p21 or p 6. In these embodiments, the promoter is most preferably derived from a gene identified in Table I. Most preferably, the promoter is derived from ORC1, PRC1, XRCC9, CDC2, cyclin B1, AIK1, CENP-A, CENP-F, MAD2, BUBRI, MCAK, HSET, CHLI, thymopoietin a, MPP2, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, Rad54, exonuclease HEX1/RAD2, PLK1, DHFR, or citron kinase. In other preferred embodiments, the promoter is derived from a cellular gene whose expression is induced by a CDK inhibitor such as p 2 1 or p16. In these embodiments, the promoter is most preferably derived from a gene identified in Table II. Most preferably, the promoter is derived from serum amyloid A, complement C3, connective tissue growth factor, integrin P-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 66 sh c, lysosomal P-galactosidase, or cathepsin B. Preferred reporter genes comprising the recombinant expression constructs of the invention include firefly luciferase, chloramphenicol acetyltransferase, -6beta-galactosidase, green fluorescent protein, or alkaline phosphatase.

In additional preferred embodiments, the invention provides a mammalian cell comprising a first recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor, most preferably p21 or p16, and a second recombinant expression construct encoding a mammalian CDK inhibitor gene, wherein expression of the CDK inhibitor is experimentally-induced in the mammalian cell thereby. In preferred embodiments, the CDK inhibitor gene is p16 or p21. In preferred embodiments, the recombinant expression construct encoding a mammalian CDK inhibitor gene is under the transcriptional control of an inducible heterologous promoter, wherein expression of the CDK inhibitor from the recombinant expression construct is mediated by contacting the recombinant cell with an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter. Preferably, the construct comprises a nucleotide sequence encoding p21, most preferably human p21. In alternative preferred embodiments, the construct comprises a nucleotide sequence encoding p16, most preferably human p16. In other embodiments, the construct comprises a nucleotide sequence encoding the amino-terminal portion of p21 comprising the CDK binding domain, more preferably comprising amino acids 1 through 78 of the p21 amino acid sequence. In a preferred embodiment, the promoter is derived from a cellular gene whose expression is repressed by a CDK inhibitor such as p21 or p16. In these embodiments, the promoter is most preferably derived from a gene identified in Table I.

In other preferred embodiments, the promoter is derived from a cellular gene whose expression is induced by a CDK inhibitor such as p21 or p 6. In these embodiments, the promoter is most preferably derived from a gene identified in Table II. Preferred reporter genes comprising the recombinant expression constructs of the invention include firefly luciferase, chloramphenicol acetyltransferase, beta-galactosidase, green fluorescent protein, or alkaline phosphatase. In a preferred embodiment, the mammalian cell is a fibrosarcoma cell.

In a second aspect, the invention provides a conditioned cell culture medium wherein the medium is conditioned by cells expressing a CDK inhibitor, and methods for producing said conditioned medium. In preferred embodiments, the CDK inhibitor is p21 or pl6. In preferred embodiments, the conditioned medium is produced by culturing p21- or pl6-expressing cells in a mammalian cell culture medium, most preferably a synthetic medium that does not contain serum additives. CDK inhibitor expression useful with this aspect of the invention includes both endogenous CDK inhibitor expression and inducible expression of a recombinant expression construct encoding a CDK inhibitor under the transcriptional control of an inducible promoter.

Preferred CDK inhibitors include p21 and p16. Preferred cells include mammalian cells, preferably rodent or primate cells, and more preferably mouse or human cells. A particularly preferred embodiment is fibrosarcoma cells, more preferably human fibrosarcoma cells and most preferably human HT1080 fibrosarcoma cell line and derivatives thereof.

This aspect of the invention also provides a screening method for identifying compounds that inhibit CDK inhibitor- induced expression of mitogenic or antiapoptotic factors in mammalian cells. In preferred embodiments, the method comprises the steps of inducing the expression of a CDK inhibitor, most preferably p21 or p16, in the cells in the presence or absence of a compound, and comparing expression of a -8mitogen or anti-apoptotic compound, or a plurality thereof, in the conditioned media.

Inhibitors of CDK inhibitor effects are identified by having a lesser amount of the mitogen or anti-apoptotic compound, or a plurality thereof, in the conditioned media in the presence of the compound than in the absence of the compound. In the methods provided in this aspect of the invention, any CDK inhibitor-expressing cell is useful, most preferably cells expressing p21 or pl6, and p21 or p16 expression in such cells can be achieved by inducing endogenous p21 or p16, or by using cells containing an inducible expression construct encoding p21 or p16 according to the invention.

Preferred cells include mammalian cells, preferably rodent or primate cells, and more preferably mouse or human cells. In a particularly preferred embodiment are fibrosarcoma cells, more preferably human fibrosarcoma cells and most preferably human HT1080 fibrosarcoma cell line and derivatives thereof.

In alternative embodiments, the invention provides methods for identifying compounds that inhibit CDK inhibitor- induced expression of mitogenic or antiapoptotic factors in mammalian cells, wherein the cells comprise a recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter of a cellular gene that is induced by a CDK inhibitor such as p21 or p16. In preferred embodiments, promoters include the promoters for CTGF, activin A, epithelin/granulin, galectin-3 and prosaposin. Preferred reporter genes include but are not limited to firefly luciferase, 0-galactosidase, alkaline phosphatase and green fluorescent protein. In these embodiments, inhibition of CDK inhibitor-mediated induction of reporter gene expression is used to identify compounds that inhibit induction of mitogens or anti-apoptotic factors in CDKI inhibitor-expressing cells.

In this aspect, the invention also provides a method for inhibiting production of -9mitogenic or anti-apoptotic factors or compounds in a mammalian cell, the method comprising the steps of contacting the cell with a compound that inhibits production of mitogenic or anti-apoptotic factors, wherein said compound is identified by the aforesaid methods of this aspect of the invention. In preferred embodiments, the mammalian cells contacted with the inhibitory compounds in which production of mitogenic or antiapoptotic factors is inhibited are fibroblasts, most preferably stromal fibroblasts.

In a third aspect, the invention provides methods for identifying compounds that inhibit CDK inhibitor-mediated modulation of cellular gene expression. These methods comprise the steps of inducing or otherwise producing a CDK inhibitor in a mammalian cell; assaying the cell in the presence of the compound for changes in expression of cellular genes whose expression is modulated by the CDK inhibitor; and identifying compounds that inhibit CDK inhibitor-mediated modulation of cellular gene expression if expression of the cellular genes is changed to a lesser extent in the presence of the compound than in the absence of the compound. In preferred embodiments, the CDK inhibitor is p21 or p16. In preferred embodiments, the cellular genes are repressed by a CDK inhibitor, and inhibitors are detected by detecting expression of the genes at levels greater than those detected when the CDK inhibitor is expressed in the absence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the genes are identified in Table I. In alternative preferred embodiments, the cellular genes are induced by a CDK inhiibitor, and inhibitors are detected by detecting expression of the genes at levels less than those detected when the CDK inhibitor is expressed in the absence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the genes are identified in Table II. In further alternative embodiments, the method is performed using a recombinant mammalian cell comprising a reporter gene under the transcriptional control of a promoter derived from a gene whose expression is modulated by a CDK inhibitor. In these embodiments using constructs comprising promoters derived from genes repressed by the CDK inhibitor, the reporter gene product is produced at greater levels in the presence than in the absence of the compound when the compound is an inhibitor of CDK inhibitor-mediated gene expression modulation. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p 1 6. In these embodiments, the promoter is most preferably derived from a gene identified in Table I. Most preferably, the promoter is derived from ORCI, PRCI, XRCC9, CDC2, cyclin BI, AIK1, CENP-A, CENP-F, MAD2, BUBR1, MCAK, HSET, CHLI, thymopoietin a, MPP2, MPPS, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, Rad54, exonuclease HEX1/RAD2, PLKI, DHFR or citron kinase. When using constructs comprising promoters derived from genes induced by a CDK inhibitor, the reporter gene product is produced at lesser levels in the presence than the absence of the compound when the compound is an inhibitor of CDK inhibitor-mediated gene expression modulation. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In these embodiments, the promoter is most preferably derived from a gene identified in Table II. Most preferably, the promoter is derived from serum amyloid A, complement C3, connective tissue growth factor, integrin P-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 6 6 she lysosomal P-galactosidase, or cathepsin B.

Preferred reporter genes comprising the recombinant expression constructs of the invention include firefly luciferase, chloramphenicol acetyltransferase, beta- -11galactosidase, green fluorescent protein, or alkaline phosphatase. In other preferred embodiments, the cell comprises a first recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor, and a second recombinant expression construct encoding a mammalian CDK inhibitor gene, wherein expression of the CDK inhibitor is experimentally-induced in the mammalian cell thereby. The product of the reporter gene or the endogenous gene that is induced or repressed by the CDK inhibitor is detected using an immunological reagent, by assaying for an activity of the gene product, or by hybridization to a complementary nucleic acid. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p 16.

In a fourth aspect, the invention provides methods for identifying compounds that inhibit senescence in a mammalian cell. These methods comprise the steps of treating the mammalian cell in the presence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence; assaying the mammalian cell for repression or induction of genes that are repressed or induced by CDK inhibitor gene expression; and identifying the compound as an inhibitor of senescence if genes that are repressed by the CDK inhibitor are not repressed, or genes that are induced by the CDK inhibitor are not induced, in the presence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16.

In preferred embodiments, the cellular genes are repressed by the CDK inhibitor, and senescence inhibitors are identified by detecting expression of the genes at levels greater than those detected when CDK inhibitor is expressed in the absence of the compound.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p 16. In preferred embodiments, the genes are identified in Table I. In alternative -12preferred embodiments, the cellular genes are induced by a CDK inhibitor, and senescence inhibitors are detected by detecting expression of the genes at levels less than those detected when the CDKI inhibitor is expressed in the absence of the compound.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the genes are identified in Table II. In further alternative embodiments, the method is performed using a recombinant mammalian cell comprising a reporter gene under the transcriptional control of a promoter derived from a gene whose expression is modulated by a CDK inhibotor. In these embodiments, production of the product of the reporter gene at greater levels in the presence than in the absence of the compound when using constructs comprising promoters derived from genes repressed by the CDK inhibitor, or at lesser levels in the presence than the absence of the compound when using constructs comprising promoter derived from genes induced by the CDK inhibitor, is detected when the compound is an inhibitor of senescence. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. The promoters are preferably derived from genes identified in Table I (for genes repressed by a CDK inhibitor) or Table II (for genes induced by a CDK inhibitor). For p21 -repressed genes, the promoter is most preferably derived from ORC1, PRC1, XRCC9, CDC2, cyclin B1, AIK1, CENP-A, CENP-F, MAD2, BUBR1, MCAK, HSET, CHLI, thymopoietin a, MPP2, MPPS, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, Rad54, exonuclease HEX /RAD2, PLKI, DHFR or citron kinase. For CDK inhibitor-induced genes, the promoter most preferably is derived from serum amyloid A, complement C3, connective tissue growth factor, integrin P-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 6 6 s e lysosomal B-galactosidase, 13 or cathepsin B. In other preferred embodiments, the cell comprises a first recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor, and a second recombinant expression construct encoding a mammalian CDK inhibitor gene, wherein expression of the CDK inhibitor is experimentally-induced in the mammalian cell thereby. The product of the reporter gene or the endogenous gene that is induced or repressed by the CDK inhibitor is detected using an immunological reagent, by assaying for an activity of the gene product, or by hybridization to a complementary nucleic acid.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p 21 orpl6.

In a fifth aspect, the invention provides methods for inhibiting cellular senescence, age-related diseases or age-associated gene products, the method comprising the steps of contacting the cell with a compound that inhibits senescence as determined using the methods provided in the aforesaid aspects of the invention.

In a sixth aspect, the invention provides methods for identifying compounds that potentiate senescence in a mammalian cell. These methods comprise the steps of inducing expression of a CDK inhibitor in the mammalian cell in the presence and absence of the compound; assaying the mammalian tumor cell for repression or induction of genes that are repressed or induced by CDK inhibitor gene expression; and identifying the compound as a potentiator of senescence if genes that are repressed by the CDK inhibitor are repressed to a greater extent, or genes that are induced by the CDK inhibitor are induced to a greater extent, in the presence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the cellular genes are repressed by a CDK inhibitor, -14and potentiators are detected by detecting expression of the cellular gene at levels less than those detected when the CDK inhibitor is expressed in the absence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the genes are identified in Table I. In alternative preferred embodiments, the cellular genes are induced by a CDK inhibitor, and potentiators are detected by detecting expression of the cellular gene at levels greater than those detected when the CDK inhibitor is expressed in the absence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the genes are identified in Table II.

In further alternative embodiments, the method is performed using recombinant mammalian cells comprising a reporter gene under the transcriptional control of a promoter derived from a gene whose expression is modulated by a CDK inhibitor, wherein the cells comprise constructs having the reporter gene under the transcriptional control of promoters from genes whose expression is modulated by the CDK inhibitor.

In these embodiments, production of the product of the reporter gene at lower levels in the presence than in the absence of the compound when using constructs comprising promoters derived from genes repressed by a CDK inhibitor, or at greater levels in the presence than the absence of the compound when using constructs comprising promoter derived from genes induced by a CDK inhibitor, is detected when the compound is a potentiator of senescence. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the promoters are derived from genes whose expression is repressed by a CDK inhibitor, most preferably genes identified in Table I. Most preferably, the promoter is derived from ORC 1, PRC 1, XRCC9, CDC2, cyclin B 1, AIK1, CENP-A, CENP-F, MAD2, BUBR1, MCAK, HSET, CHL1, thymopoietin a, MPP2, MPP5, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, Rad54, exonuclease HEX I/RAD2, PLKI, DHFR or citron kinase.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In alternative preferred embodiments, the promoters are derived from genes whose expression is induced by a CDK inhibitor, most preferably genes identified in Table II. Most preferably, the promoter is derived from serum amyloid A, complement C3, connective tissue growth factor, integrin P-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p66 sh lysosomal p-galactosidase, or cathepsin B. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16.

In other preferred embodiments, the cell comprises a first recombinant expression construct encoding a reporter gene under the transcriptional control of a. promoter for a mammalian gene whose expression is modulated by a CDK inhibitor, and a second recombinant expression construct encoding a mammalian CDK inhibitr gene, wherein expression of the CDK inhibitor is experimentally-induced in the mammalian cell thereby. The product of the reporter gene or the endogenous gene that is induced or repressed by the CDK inhibitor is detected using an immunological reagent, by assaying for an activity of the gene product, or by hybridization to a complementary nucleic acid.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p6.

In a seventh aspect, the invention provides methods for promoting or potentiating cellular senescence in tumor cells, hyperplastic cells or any cell type that is pathological or disease-causing due to excessive proliferation, the method comprising the steps of contacting the cell with a compound that potentiates senescence as determined using the 16methods provided in the aforesaid aspect of the invention.

In a eighth aspect, the invention provides compounds that are identified using any of the methods of the invention as disclosed herein.

In a ninth aspect, the invention provides methods for obtaining a plurality of nucleic acid species enriched for genes involved in cell cycle progression. These methods comprise the steps of inducing the expression of a CDK inhibitor in a mammalian cell; obtaining cellular mRNA from a mammalian cell before p21 induction and after p21 is induced and cell growth is stopped; and obtaining the plurality of nucleic acid species enriched for genes involved in cell cycle progression. In a preferred embodiment, the plurality of nucleic acid species enriched for cell cycle progression genes is obtained by subtractive hybridization methods known in the art, whereby nucleic acid species underrepresented in cells expressing p21 are selectively enriched.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p!6.

In a tenth aspect, the invention provides methods for obtaining a plurality of nucleic acid species enriched for genes that encode secreted proteins with paracrine functions and proteins involved in senescence and age-related diseases. These methods comprise the steps of inducing expression of a CDK inhibitor in a mammalian cell; obtaining cellular mRNA from a mammalian cell before and after the CDK inhibitor is induced; and obtaining the plurality of nucleic acid species enriched for genes whose expression is increased in the cell after the CDK inhibitor is induced. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p 16.

In preferred embodiments, the paracrine functions of the proteins are mitogenic and antiapoptotic effects. In a preferred embodiment, the plurality of nucleic acid species -17enriched for genes that encode secreted proteins with paracrine functions and proteins involved in senescence and age-related diseases is obtained by subtractive hybridization methods known in the art, whereby nucleic acid species overrepresented in cells expressing a CDK inhibitor are selectively enriched.

In an eleventh aspect, the invention provides a method for identifying genes that are markers of cellular senescence, the method comprising the steps of inducing senescence by producing expression of a CDK inhibitor in a first population of mammalian cells and inducing quiescence in a second population of mammalian cells; obtaining mRNA from each population of cells; comparing the pattern of gene expression in cells before and after production of the CDK inhibitor in the cells with the pattern of gene expression in cells before and after the cells became quiescent; comparing the plurality of genes strongly induced in the cells after the CDK inhibitoris produced with the plurality of genes strongly induced in quiescent cells; and identifying the genes strongly induced in cells producing the CDK inhibitor that are not strongly induced in quiescent cells. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16.

In a twelfth aspect, the invention provides methods for detecting senescence in a mammalian cell. These methods comprise the step of detecting expression ofa gene that is a marker for senescence. In preferred embodiments, preferred markers of senescence include connective tissue growth factor (CTGF), serum amyloid A, integrin 3-3, activin A, natural killer cell protein 4, Mac2 binding protein, or tissue transglutaminase.

In a thirteenth aspect, the invention provides methods for identifying compounds that promote induction of senescence in a mammalian cell. These methods comprise the steps of treating the mammalian cell with an agent or culturing the mammalian cell -18under conditions that induce senescence in the presence of the compound; assaying the mammalian tumor cell for repression or induction of genes that are repressed or induced by CDK inhibitorgene expression; and identifying the compound as a potentiator of senescence if genes that are repressed by the CDK inhibitor are further repressed, to a greater extent, or genes that are induced by the CDK inhibitor are further induced, i.e., to a greater extent, in the presence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the cellular genes are repressed by the CDK inhibitor, and compounds that promote induction of senescence are detected by detecting expression of the cellular gene at levels less than those detected when the CDK inhibitor is expressed in the absence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the genes are identified in Table I. In alternative preferred embodiments, the cellular genes are induced by a CDK inhibitor, and compounds that promote induction of senescence are detected by detecting expression of the cellular gene at levels greater than those detected when the CDK inhibitor is expressed in the absence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p2 1 or p16.

In preferred embodiments, the genes are identified in Table II. In further alternative embodiments, the method is performed using recombinant mammalian cells comprising a reporter gene under the transcriptional control of a promoter derived from a gene whose expression is modulated by a CDK inhibitor, wherein the cells comprise constructs having the reporter gene under the transcriptional control of promoters from genes whose expression is modulated by a CDK inhibitor. In these embodiments, production of the product of the reporter gene at lower levels in the presence than in the -19absence of the compound when using constructs comprising promoters derived from genes repressed by the CDK inhibitor, or at greater levels in the presence than the absence of the compound when using constructs comprising promoter derived from genes induced by a CDK inhibitor, is detected when the compound promotes induction of senescence. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p 16. In preferred embodiments, the promoters are derived from genes whose expression is repressed by a CDK inhibitor, most preferably genes identified in Table I. Most preferably, the promoter is derived from ORCI, PRC1, XRCC9, CDC2, cyclin B 1, AIK 1, CENP-A, CENP-F, MAD2, BUBR I, MCAK, HSET, CHLI, thymopoietin a, MPP2, MPP5, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, Rad54, exonuclease HEX I/RAD2, PLK1, DHFR or citron kinase.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In alternative preferred embodiments, the promoters are derived from genes whose expression is induced by CDK inhibitor, most preferably genes identified in Table II. Most preferably, the promoter is derived from serum amyloid A, complement C3, connective tissue growth factor, integrin P-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 66 sh, lysosomal P-galactosidase, or cathepsin B. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p 16.

In other preferred embodiments, the cell comprises a first recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor, and a second recombinant expression construct encoding a mammalian CDK inhibitorgene, wherein expression of the CDK inhibitor is experimentally-induced in the mammalian cell thereby. The product of the reporter gene or the endogenous gene that is induced or repressed by a CDK inhibitor is detected using an immunological reagent, by assaying for an activity of the gene product, or by hybridization to a complementary nucleic acid.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 orpl6.

In a fourteenth aspect, the invention provides methods for identifying compounds that induce senescence in a mammalian cell. These methods comprise the steps of assaying a mammalian cell in the presence and absence of the compound for repression or induction of genes that are repressed or induced by CDK inhibitor gene expression; and identifying compounds that induce senescence if genes that are repressed by the CDK inhibitor are repressed, or genes that are induced by the CDK inhibitor are induced, in the presence of the compound. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the cellular genes are repressed by the CDK inhibitor, and compounds that induce senescence are detected by detecting expression of the cellular gene at levels less than those detected in the absence of the compound. In preferred embodiments, the genes are identified in Table I. In alternative preferred embodiments, the cellular genes are induced by the CDK inhibitor, and compounds that induce senescence are detected by detecting expression of the cellular gene at levels greater than those detected in the absence of the compound. In preferred embodiments, the genes are identified in Table II. In further alternative embodiments, the method is performed using recombinant mammalian cells comprising a reporter gene under the transcriptional control of a promoter derived from a gene whose expression is modulated by a CDK inhibitor, wherein the cells comprise constructs having the reporter gene under the transcriptional -21 control of promoters from genes whose expression is modulated by the CDK inhibitor 1.

In these embodiments, production of the product of the reporter gene at lower levels in the presence than in the absence of the compound when using constructs comprising promoters derived from genes repressed by the CDK inhibitor or at greater levels in the presence than the absence of the compound when using constructs comprising promoter derived from genes induced by the CDK inhibitor, is detected when the compound induces senescence. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16. In preferred embodiments, the promoters are derived from genes whose expression is repressed by a CDK inhibitor, most preferably genes identified in Table I. Most preferably, the promoter is derived from ORC1, PRC1, XRCC9, CDC2, cyclin B 1, AIK 1, CENP-A, CENP-F, MAD2, BUBR 1, MCAK, HSET, CHL1, thymopoietin a, MPP2, MPP5, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, Rad54, exonuclease HEXl/RAD2, PLK1, DHFR or citron kinase.

In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p 2 1 or p 16. In alternative preferred embodiments, the promoters are derived from genes whose expression is induced by a CDK inhibitor, most preferably genes identified in Table II. Most preferably, the promoter is derived from serum amyloid A, complement C3, connective tissue growth factor, integrin 1-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 6 6 sh e lysosomal P-galactosidase, or cathepsin B. The product of the reporter gene or the endogenous gene that is induced or repressed by a CDK inhibitor is detected using an immunological reagent, by assaying for an activity of the gene product, or by hybridization to a complementary nucleic acid. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p16.

22 Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic diagram of the IPTG-regulated retroviral vector LNp21C03 used to produce the human HT1080 fibrosarcoma cell line variant p21-9.

Figure 2A is a graph of the time course of p21 induction after the addition of iM IPTG, where p21 levels were determined by ELISA.

Figure 2B is a graph of the time course of p21 decay after removal of IPTG.

Figure 3A is a graph of the time course of changes in 3 H-thymidine labeling index (as determined by autoradiography) after the addition of 50 pM IPTG.

Figure 3B is a graph of the time course of changes in mitotic index (as determined by microscopy after DAPI staining) after the addition of 50 UM IPTG.

Figure 3C is a graph of the time course of changes in cell cycle distribution (determined by fluorescence-activated cell sorting (FACS) analysis following propidium iodide) after the addition of 50 gM IPTG; cells in G1 phase of the cell cycle; cells in G2/M phase of the cell cycle; cells in S phase of the cell cycle.

-23- Figure 4A is a graph showing the effects of the duration of treatment with different doses of IPTG on colony formation by p21-9 cells; 0.5 pM IPTG; IPTG; 50p.M IPTG.

Figure 4B is a graph of the time course of changes in 3 H-thymidine labeling index (determined by autoradiography) after the removal of 50 jtM IPTG; 1 day; 5 days.

Figure 4C is a graph of the time course of changes in mitotic index (determined by microscopy) after the removal of 50 p.M IPTG; 1 day; 5 days.

Figure 4D is a graph of the time courses of changes in the percentage of floating cells after the removal of 50 pM IPTG following one day or three days of treatment; untreated; 1 day; 3 days.

Figure 5A is a histogram showing changes in PKH2 fluorescence profiles of untreated cells (left) and cells treated for 5 days with 50 pM IPTG and released in IPTGfree media (right), as determined by FACS.

Figure 5B is a graphical representation of FACS profiles of DNA content of PKH2I°SS'O (thin line) and PKH2hiSShi (thick line) cell populations isolated by FACS after 5-day treatment with 50 pM IPTG, PKH2 labeling, and 6-day growth without

IPTG.

24 Figure 5C is a graphical representation of FACS profiles of DNA content of floating cells, collected 48 hrs after release from 3-day treatment with 50 gtM IPTG (left) and from untreated cells (right).

Figure 5D is a graphical representation of FACS profiles of DNA content of attached cells at Oh, 12h, 24h, 28h, 36h and 48h after release from 1 -day IPTG treatment.

Figure 6 are photomicrographs illustrating examples of normal (left) and abnormal (right) mitotic figures observed 1-2 days after release from IPTG (DAPI staining; photographed at 1,000 x magnification.

Figure 7A are photographs of gel electrophoresis patterns of RT-PCR experiments (left), northern blot analysis of cellular mRNA expression (middle) and immunoblotting assays for IPTG-induced changes in expression of the denoted genes; C: control untreated p21-9 cells; I: cells treated for 3 days with 50 PM IPTG. 32microglobulin (B2-M) was used as a normalization control for RT-PCR and S14 ribosomal protein gene for northern hybridization.

Figure 7B are photographs of gel electrophoresis of RT-PCR experiments (left) and immunoblotting analysis (right) showing the time course of changes in the expression of the denoted p21-inhibited genes upon IPTG addition and release.

Figure 7C are photographs of gel electrophoresis patterns of RT-PCR experiments (left) and northern hybridization analysis (right) of the time course of changes in the expression of the denoted p21-induced genes upon IPTG addition.

Figure 7D is a comparison of gene expression in untreated control p21-9 cells serum-starved quiescent cells and IPTG-treated senescent cells Figure 8A is a histogram showing the effects of fresh media conditioned media from IPTG-treated or untreated p21-9 cells and 1:1 mixtures of conditioned and fresh media (I/F and supplemented with 1% or 2% serum, on 3

H-

thymidine incorporation by HS 15.T cells.

Figure 8B are graphical representations of FACS profiles of the DNA content of combined attached and floating C8 cells after 24 hr or 48 hr incubation in 10% serum (control), in low-serum fresh media or in conditioned media from IPTG-treated or untreated p21-9 cells. Relative numbers of attached cells (as determined by methylene blue staining) after 48 hr incubation in the same media are listed beneath each set of histograms.

Figure 9 is a histogram of luciferase activity in cells containing a construct in which luciferase is under the transcriptional control of a promoter from a gene the expression of which is modulated by p21. Expression in the absence (no IPTG, shown as open bars) and presence (with the addition of 50 IpM IPTG, shown as shaded bars) of p21 expression is shown for constructs prepared according to Example 6 containing promoters from polo-like kinase (PLK natural killer cell protein 4 (NK4), and serum amyloid A (SAA); each promoter construct tested using 2 independent construct clones.

-26- Figure 10 is a schematic diagram of the IPTG-regulated retroviral vector LNp16RO2 used to produce the human HT1080 fibrosarcoma cell line variant HT1080/ LNpl6R02.

Figure 11 is a graph of the time course of cell growth of HT1080 3'SS6 cells containing LNp 6R02 (as determined by light scattering at 600nm) after the addition of 50 LM IPTG; untreated; IPTG-treated.

Figure 12 are photographs of gel electrophoresis patterns of RT-PCR experiments using cells containing LNp6RO2 for detecting IPTG-induced changes in expression of the denoted genes; C: control untreated cells; I: cells treated for 3 days with 50 p.M IPTG. p-actin was used as a normalization control for RT-PCR.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS This invention provides reagents and methods for identifying genes involved in mediating CDK inhibitor-induced cellular senescence, and compounds capable of inhibiting or potentiating senescence or quiescence in mammalian cells. Particularly provided are embodiments of such reagents and methods for identifying genes involved in cellular senescence and induced by CDK inhibitors p21 or p16.

For the purposes of this invention, the term "CDK inhibitor" is intended to encompass members of a family of mammalian genes having the enzymatic activity of cyclin-dependent kinase inhibition. Explicitly contained in this definition are the CDK -27inhibitors p27, p15, p14, p 18 and particularly p16 and p21, the latter two of which are particularly preferred embodiments of the reagents and methods of this invention.

For the purposes of this invention, reference to "a cell" or "cells" is intended to be equivalent, and particularly encompasses in vitro cultures of mammalian cells grown S and maintained as known in the art.

For the purposes of this invention, reference to "cellular genes" in the plural is intended to encompass a single gene as well as two or more genes. It will also be understood by those with skill in the art that effects of modulation of cellular gene expression, or reporter constructs under the transcriptional control of promoters derived from cellular genes, can be detected in a first gene and then the effect replicated by.

testing a second or any number of additional genes or reporter gene constructs.

Alternatively, expression of two or more genes or reporter gene constructs can be assayed simultaneously within the scope of this invention.

For the purposes of this invention, the term "quiescence" will be understood to encompass temporary cessation of cell growth and DNA replication such as occurs in cultured mammalian cells under conditions of serum starvation.

For the purposes of this invention, the term "senescence" will be understood to include permanent cessation of DNA replication and cell growth not reversible by growth factors, such as occurs at the end of the proliferative lifespan of normal cells or in normal or tumor cells in response to cytotoxic drugs, DNA damage or other cellular insult.

Senescence can be induced in a mammalian cell in a number of ways. The first is a natural consequence of normal cell growth, either in vivo or in vitro: there are a limited number of cell divisions, passages or generations that a normal cell can undergo -28before it becomes senescent. The precise number varies with cell type and species of origin (Hayflick Moorhead, 1961, Exp. Cell Res. 25: 585-621). Another method for inducing senescence in any cell type is treatment with cytotoxic drugs such as most anticancer drugs, radiation, and cellular differentiating agents. See, Chang et al., 1999, Cancer Res. 59: 3761-3767. Senescence also can be rapidly induced in any mammalian cell by transducing into that cell a tumor suppressor gene (such as p53, p 2 1, p16 or Rb) and expressing the gene therein. See. Sugrue et al., 1997, Proc. Natl. Acad. Sci. USA 94: 9648-9653; Uhrbom et al., 1997, Oncogene 15: 505-514; Xu et al., 1997, Oncogene 2589-2596; Vogt et al., 1998, Cell Growth Differ. 9: 139-146 The reagents of the present invention include any mammalian cell, preferably a rodent or primate cell, more preferably a mouse cell and most preferably a human cell, that can induces expression of a CDK inhibitor gene, most preferably the p21 gene or p16 gene, wherein such gene is either the endogenous gene or an exogenous gene introduced by genetic engineering. Although the Examples disclose recombinant mammalian cells comprising recombinant expression constructs encoding inducible p21 and p16 genes, it will be understood that these embodiments are merely a matter of experimental design choice and convenience, and that the invention fully encompasses induction of endogenous CDK inhibitor genes such as p21 and p16 In preferred embodiments, the invention provides mammalian cells containing a recombinant expression construct encoding an inducible mammalian p21 gene. In preferred embodiments, the p21 gene is human p21 having nucleotide and amino acid sequences as set forth in U.S. Patent No. 5,424,400, incorporated by reference herein. In alternative embodiments, the p21 gene is an amino-terminal portion of the human p21 gene, preferably comprising amino acid residues 1 through 78 of the native human p21 -29protein (as disclosed in U.S. Patent No. 5,807,692, incorporated by reference) and more preferably comprising the CDK binding domain comprising amino acids 21-71 of the native human p21 protein (Nakanishi et al., 1995, EMBO J. 14: 555-563). Preferred host cells include mammalian cells, preferably rodent or primate cells, and more preferably mouse or human cells. Particularly preferred embodiments are fibrosarcoma cells, more preferably human fibrosarcoma cells and most preferably human HT1080 fibrosarcoma cell line and derivatives thereof. A most preferred cell line is an HT 1080 fibrosarcoma cell line derivative identified as p21-9, deposited on April 6, 2000 with the American Type Culture Collection, Manassas, Virginia U.S.A. under Accession No.

PTA 1664.

In alternative preferred embodiments, the invention provides mammalian cells containing a recombinant expression construct encoding an inducible mammalian p16 gene. In preferred embodiments, the p16 gene is human p16 having nucleotide and amino acid sequences as set forth in Serrano et al., 1993, Nature 366: 704-707, incorporated by reference herein. Preferred host cells include mammalian cells, preferably rodent or primate cells, and more preferably mouse or human cells.

Particularly preferred embodiments are fibrosarcoma cells, more preferably human fibrosarcoma cells and most preferably human HT1080 fibrosarcoma cell line and derivatives thereof. A most preferred cell line is an HT 1080 fibrosarcoma cell line derivative identified as HT1080/LNpl6RO2, deposited on October 10, 2000 with the American Type Culture Collection, Manassas, Virginia U.S.A. under Accession No.

PTA-2580.

Recombinant expression constructs can be introduced into appropriate mammalian cells as understood by those with skill in the art. Preferred embodiments of said constructs are produced in transmissible vectors, more preferably viral vectors and most preferably retrovirus vectors, adenovirus vectors, adeno-associated virus vectors, and vaccinia virus vectors, as known in the art. See, generally, MAMMALIAN CELL BIOTECHNOLOGY: A PRACTICAL APPROACH, (Butler, Oxford University Press: New York, 1991, pp. 57-84.

In additionally preferred embodiments, the recombinant cells of the invention contain a construct encoding an inducible CDK inhibitorgene, wherein the gene is under the transcriptional control of an inducible promoter. In more preferred embodiments, the inducible promoter is responsive to a trans-acting factor whose effects can be modulated by an inducing agent. The inducing agent can be any factor that can be manipulated experimentally, including temperature and most preferably the presence or absence of an inducing agent. Preferably, the inducing agent is a chemical compound; most preferably a physiologically-neutral compound that is specific for the trans-acting factor. In the use of constructs comprising inducible promoters as disclosed herein, expression of CDK inhibitor from the recombinant expression construct is mediated by contacting the recombinant cell with an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter. In preferred embodiments of this aspect of the inventive methods, the CDK inhibitor is p21 or p 16. A variety of inducible promoters and cognate trans-acting factors are known in the prior art, including heat shock promoters than can be.activated by increasing the temperature of the cell culture, and more preferably promoter/factor pairs such as the tet promoter and fusions thereof with mammalian transcription factors (as are disclosed in U.S. Patent Nos. 5,654,168, 5,851,796, and 5,968,773), and the bacterial lac promoter of the lactose operon and its cognate lacI repressor protein. In a preferred embodiment, the -31 recombinant cell expresses the lacl repressor protein and a recombinant expression construct encoding human p21 under the control of a promoter comprising one or a multiplicity of lac-responsive elements, wherein expression of p21 can be induced by contacting the cells with the physiologically-neutral inducing agent, isopropylthio-Pgalactoside. In this preferred embodiment, the lacI repressor is encoded by a recombinant expression construct identified as 3'SS (commercially available from Stratagene, LaJolla, CA). In alternative preferred embodiments, the recombinant cell expresses the lacI repressor protein and a recombinant expression construct encoding human p16 under the control of a promoter comprising one or a multiplicity of lacresponsive elements, wherein expression of p 6 can be induced by contacting the cells with the physiologically-neutral inducing agent, isopropylthio-P-galactoside. In this preferred embodiment, the lacI repressor is encoded by the 3'SS recombinant expression construct (Stratagene).

The invention also provides recombinant expression constructs wherein a reporter gene is under the transcriptional control of a promoter of a gene whose expression is modulated by a CDK inhibitor such as p21 or p16. These include genes whose expression is induced by CDK inhibitors and genes whose expression is repressed by CDK inhibitors. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p 2 1 or p 16. In preferred embodiments, the promoters are derived from genes whose expression is repressed by a CDK inhibitor, and are identified in Table I. Most preferably, the promoter is derived from ORCI, PRC1, XRCC9, CDC2, cyclin Bl, AIKI, CENP-A, CENP-F, MAD2, BUBR1, MCAK, HSET, CHLI, thymopoietin a, MPP2, MPP5, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, Rad54, exonuclease HEX1/RAD2, PLK1, DHFR or citron kinase. In additional 32preferred embodiments, the promoters are derived from genes whose expression is induced or otherwise increased by CDK inhibitor expression, and are identified in Table II. Most preferably, the promoter is derived from serum amyloid A, complement C3, connective tissue growth factor, integrin P-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p66 h lysosomal P-galactosidase, or cathepsin B. These reporter genes are then used as sensitive and convenient indicators of the effects of CDK inhibitor gene expression, and enable compounds that inhibit or potentiate the effects of CDK inhibitorexpression in mammalian cells to be easily identified. Host cells for these constructs include any cell in which CDK inhibitorgene expression can be induced, and preferably include cells also containing recombinant expression constructs containing an inducible CDK inhibitor gene as described above. Reporter genes useful in the practice of this aspect of the invention include but are not limited to firefly luciferase, chloramphenicol acetyltransferase, beta-galactosidase, green fluorescent protein, and alkaline phosphatase.

In preferred embodiments, cells according to the invention comprise both a first recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor, and a second recombinant expression construct encoding a mammalian CDK inhibitor gene, wherein CDK inhibitor expression is experimentally-inducible thereby in the mammalian cell. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16.

In alternative embodiments, the invention provides a mammalian cell comprising a recombinant expression construct encoding a reporter gene under the transcriptional -33control of a promoter for a mammalian gene whose expression is repressed by a CDK inhibitor, wherein the promoter is from the gene ORC1, PRC1, XRCC9, CDC2, cyclin B 1, AIKi, CENP-A, CENP-F, MAD2, BUBR MCAK, HSET, CHLI, thymopoietin a, MPP2, MPP5, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, Rad54, exonuclease HEX1/RAD2, PLK1, DHFR or citron kinase. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p 16. In further alternative embodiments, the invention provides a mammalian cell comprising a recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is induced by a CDK inhibitor, wherein the promoter is from the gene connective tissue growth factor, serum amyloid A, complement C3, integrin 0-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 6 6 s h e lysosomal P-galactosidase, or cathepsin B. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16.

The invention provides a conditioned cell culture medium wherein the medium is conditioned by cells expressing a CDK inhibitor, and methods for producing said conditioned medium. As used herein, the term "conditioned media" is intended to encompass cell culture media conditioned by growth of CDK inhibitor--expressing cells that contains mitogenic or anti-apoptotic factors. The conditioned media is produced in a preferred embodiment by culturing CDK inhibitor--expressing cells in a mammalian cell culture medium, most preferably a synthetic medium that does not contain serum additives. Any CDK inhibitor-expressing cell is useful for the production of said conditioned media, and CDK inhibitor expression in such cells can be achieved by inducing endogenous CDK inhibitors (such as by treatment with DNA damaging agents, ionizing or ultraviolet radiation, or contact inhibition) or by using cells containing an inducible CDK inhibitor expression construct according to the invention and culturing the cells in a physiologically-neutral inducing agent. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16. Preferred cells include mammalian cells, preferably rodent or primate cells, and more preferably mouse or human cells. A particularly preferred embodiment are fibrosarcoma cells, more preferably human fibrosarcoma cells and most preferably human HT1080 fibrosarcoma cell line and derivatives thereof.

The invention also provides a screening method for identifying compounds that inhibit CDK inhibitor-induced expression of mitogenic or anti-apoptotic factors in mammalian cells. In preferred embodiments, CDK inhibitor expression is induced in a mammalian cell culture in the presence or absence of compounds to be identified as inhibitors of CDK inhibitor- induced expression of mitogenic or anti-apoptotic factors.

Compounds are identified as inhibitors by inducing expression of CDK inhibitorin the cells, and comparing the extent of expression of a mitogenic or anti-apoptotic factor, or a plurality thereof, in the presence of the compound with expression in the absence of the compound, and inhibitors identified as compounds that have a reduced amount of expression of a mitogenic or anti-apoptotic factor, or a plurality thereof, in the presence of the compound. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16. Any CDK inhibitor-expressing cell is useful for the production of said conditioned media, and CDK inhibitorexpression in such cells can be achieved by inducing endogenous CDK inhibitors (such as by treatment with DNA damaging agents and other cytotoxic compounds, and ionizing or ultraviolet radiation, or contact inhibition) or by using cells containing an inducible CDK inhibitor expression construct according to the invention and culturing the cells in a physiologically-neutral inducing agent. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16. Preferred cells include mammalian cells, preferably rodent or primate cells, and more preferably mouse or human cells. Particularly preferred embodiments are fibrosarcoma cells, more preferably human fibrosarcoma cells and most preferably human HT1080 fibrosarcoma cell line and derivatives thereof. An exemplary cell line according to this particularly preferred embodiment of the invention is an HT 1080 fibrosarcoma cell line derivative identified as p 2 1 deposited on April 6, 2000 with the American Type Culture Collection, Manassas, Virginia U.S.A. under Accession No.

PTA 1664. Another exemplary cell line according to this particularly preferred embodiment of the invention is an HT 1080 fibrosarcoma cell line derivative identified as HT1080/LNpl 6RO2, deposited on October 10, 2000 with the American Type Culture Collection, Manassas, Virginia U.S.A. under Accession No, PTA-2580.

In alternative embodiments, the invention provides methods for identifying compounds that inhibit CDK inhibitor- induced expression of mitogenic or antiapoptotic factors in mammalian cells, wherein the cells comprise a recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter of a cellular gene that is induced by a CDK inhibitor. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p 16. Preferred promoters include the promoters for connective tissue growth factor (CTGF), serum amyloid A, complement C3, integrin P-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 6 6 s hc lysosomal p-galactosidase, and cathepsin B. Preferred reporter genes include but are not limited to firefly luciferase, p-galactosidase, alkaline -36phosphatase and green fluorescent protein, all of which are commercially available. In these embodiments, CDK inhibitor expression is induced in the cells, and the extent of expression of the reporter gene is compared in the presence of the compound with expression in the absence of the compound. Inhibitors are identified as compounds that provide a reduced amount of expression of the reporter gene in the presence of the compound. Any CDK inhibitor-expressing cell is useful in this aspect of the invention, and CDK inhibitor expression in such cells can be achieved by inducing the endogenous inhibitor gene (for example, by treatment with DNA damaging agents or other cytotoxic compounds, ionizing or ultraviolet radiation, or contact inhibition) or by using cells containing an inducible CDK inhibitor expression construct according to the invention and culturing the cells in a physiologically-neutral inducing agent. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16. Preferred cells include mammalian cells, preferably rodent or primate cells, and more preferably mouse or human cells. A particularly preferred embodiment are fibrosarcoma cells, more preferably human fibrosarcoma cells and most preferablyhuman HT1080 fibrosarcoma cell line and derivatives thereof.

The invention provides methods for identifying compounds that inhibit or promote senescence, whereby the effects of the compound are assayed by determining whether the compounds inhibit or potentiate induction or repression of genes whose expression is modulated by a CDK inhibitor. In the practice of the methods of the invention, cultured mammalian cells in which a CDK inhibitor can be induced are treated to induce the inhibitor gene, for example, by ionizing or ultraviolet radiation, or contact inhibition treatment or treatment with cytotoxic drugs, or transduced with a transmissible vector encoding a CDK inhibitor In preferred embodiments of this -37aspect of the invention, the CDK inhibitor is p21 or p16. More preferably, p21-9 cells are used in which p21 can be induced by contacting the cells with IPTG, or HT1080/LNpl6RO2 cells are used in which p16 can be induced with IPTG. Typically, cells are grown in appropriate culture media DMEM supplemented with 10% fetal calf serum (FCS) for p21-9 cells). In p21-9 cells, p21 gene expression is induced by adding IPTG to the culture media at a concentration of about 50p.M. Typically, the CDK inhibitor is induced in these cells in the presence or absence of the compound to be tested according to the methods of the invention. mRNA is then isolated from cells in which the CDK inhibitor is induced, and expression of genes that are regulated by CDK inhibitors is analyzed. Expression is compared in cells in which the CDK inhibitoris induced in the presence of the compound with expression induced in the absence of the compound, and the differences used to identify compounds that affect cellular gene expression according to the methods set forth herein. In certain embodiments, cellular gene expression is analyzed using microarrays of oligonucleotides or cellular cDNAs such as are commercially available (for example, from Genome Systems, Inc., St. Louis, MO). In alternative embodiments, genes known to be induced or repressed by CDK inhibitors are assayed. Gene expression can be assayed either by analyzing cellular mRNA or protein for one or a plurality of CDK inhibitor-modulated genes. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16. Most preferably, the genes used in these assays are genes identified in Tables I and II.

In alternative embodiments, such compounds are identified independently of CDK inhibitor-directed experimental manipulation. In such assays, cells are treated to induce senescence in any of the ways disclosed above, including but not limited to treatment with cytotoxic drugs, radiation or cellular differentiating agents, or -38introduction of a tumor suppressor gene. Expression of genes that are repressed or induced by CDK inhibitors is analyzed in the presence or absence of the test compound.

Most preferably, the genes used in these assays are genes identified in Tables I and II, using the types of mRNA and protein assays discussed above for gene expression analysis.

In alternative embodiments, the cells in which a CDK inhibitor is induced further comprise a recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter of a cellular gene that is induced or repressed by a CDK inhibitor. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16. In preferred embodiments, the cellular gene is a gene that is repressed by the CDK inhibitor, and the promoter is derived from a gene identified in Table I. Examples of known promoters for such genes include ORC1, PRC 1, XRCC9, CDC2, cyclin BI, AIKI, CENP-A, CENP-F, MAD2, BUBR1, MCAK, HSET, CHL1, thymopoietin a, MPP2, MPP5, CDC47/MCM7, CDC21/MCM4, DNA ligase I, DNA polymerase a, RAD54, HEXI/RAD2, PLKI, DHFR or citron kinase. In preferred embodiments, the cellular gene is a gene that is induced by the CDK inhibitor, and the promoter is derived from a gene identified in Table II. Examples of known promoters for such genes include connective tissue growth factor (CTGF), serum amyloid A, complement C3, integrin 0-3, activin A, natural killer cell protein 4, prosaposin, Mac2 2 0 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p66sh e lysosomal 1-galactosidase, or cathepsin B. Preferred reporter genes include but are not limited to firefly luciferase, 0-galactosidase, alkaline phosphatase and green fluorescent protein, all of which are commercially available. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16.

-39 The invention also provides methods for identifying genes mediating the effects of CDK inhibitor-induced cellular senescence. Induction ofCDK inhibitors turns out to be an integral part of cell growth arrest associated with senescence, terminal differentiation and response to cellular damage. As described in the Examples below, cDNA array hybridization-was used to investigate whether these effects were due to p2 l-induced changes in gene expression. This analysis showed that p21 selectively inhibited multiple genes involved in the control ofmitosis, DNA replication, segregation and repair. Many proteins that were induced by p21 in these experiments have been associated with senescence and aging or implicated in age-related diseases, including atherosclerosis, Alzheimer's disease, amyloidosis and arthritis. These findings suggest that cumulative effects of p21 induction may contribute to the pathogenesis of cancer and age-related diseases. In addition, a number of p2 I-activated genes encode secreted proteins with potential paracrine effects on cell growth and apoptosis. In agreement with this observation, conditioned media from p21-induced cells showed mitogenic and antiapoptotic activity.

The analyses disclosed in the Examples below showed that inhibition of cell cycle progression genes was not simply a consequence of CDK -inhibitor-induced growth arrest. As shown in the p21-inducible system, shutoff of some of these genes occurred together with cell growth arrest, and the re-expression of all the tested genes upon release from p21 preceded the re-entry of cells into cell cycle. The nature of the immediate-response genes, such as ORC1 (required for the initiation of DNA replication), topoisomerase II (which is central to DNA segregation in G2), and PLK1 (involved in the initiation of mitosis), suggested that inhibition of their expression may in fact play a causal role in the induction of growth arrest by p21. These observations formed the basis for one aspect of the methods of the invention, which provide methods for identifying genes involved in cell cycle progression in mammalian cells.

Furthermore, the biological functions of both immediate- and early-response genes indicate that their shutoff serves to maintain CDK-inhibitor-induced growth arrest.

The use of the reagents and methods of the present invention has demonstrated that release from p21-induced growth arrest results in endoreduplication and mitotic abnormalities. DNA replication and mitosis did not resume after release from IPTG until all the p21-inhibited genes were re-expressed, and DNA replication resumed considerably before mitosis. The results disclosed in the Examples below indicate that prolonged p21 induction leads to the decay of many proteins involved in cell cycle progression, including a number of proteins involved in the "quality control" of replication or mitosis. As a result of failing to regenerate the pools of such proteins by the time cells re-entered the cell cycle after release from p21, abnormal replication and abnormal mitosis ensued. For example, the production of polyploid cells was observed after release from prolonged p21-induced cell growth arrest. Endoreduplication, the process that leads to polyploidization of the cells, may be a consequence of the abrogation of mitotic checkpoint control (Hixon et al., 1998, Mol. Cell Biol. 18: 6224- 37), which could result from a lack of p21-inhibited checkpoint control proteins, such as MAD2 and BUBRI. Furthermore, polyploid cells may arise due to a failure of cytokinesis that can be triggered by a lack of cytokinesis-associated proteins Prcl, Aimi and citron kinase, which we found to be inhibited by p21.

Different mitotic abnormalities that were observed after release from p21 have been previously found to result from mutation or inhibition of proteins that control proper chromosome alignment and segregation, including the products of such p21- -41inhibited genes as MAD2, BUBRI, PLK1, AIK-1, CENP-A, CHL1 and MCAK (Li Benezra, 1996, Proc. Natl. Acad. Sci. USA 93: 10436-10440; Glover et al., 1998, Genes Develop. 12: 3777-3787; Chan et al., 1999, J. Cell Biol. 146: 941-954 The role of such proteins in p21-induced mitotic abnormalities is supported by the analysis of the time course of decay and resynthesis of mitosis control proteins. Thus, at the time of resumed mitosis (36 hrs after release), the pools of Cdc2 and Plkl, which are required for the initiation of mitosis, are regenerated to levels comparable to untreated cells (as shown in Figure 7B). In contrast, MAD2, the function of which is to prevent anaphase unless chromosomes are properly attached to the mitotic spindle, is resynthesized much less efficiently (Fig. 7B). Furthermore, MAD2 levels that remain after one day of IPTG treatment are much higher than after 3 or more days (Fig. 7B), which agrees with a lower frequency of abnormal mitosis in cells that are released after one day of p21 induction.

p21 overexpression has been reported to inhibit DNA repair (Pan et al., 1995,J.

Biol. Chem. 270: 22008-22016; Umar et al., 1996, Cell 87: 65-73). In light of our results, this effect of p21 can be attributed to the inhibition of DNA repair genes, such as XRCC9, RAD54, HEX1/RAD2, RAD21 homolog and DNA ligase I. Inhibition of DNA repair is also likely to increase the frequency of mutations in cells that recover from p21-induced growth arrest, contributing to the overall genetic instability of such cells.

p21-induced genetic destabilization in normal cells may also have a potential carcinogenic effect. Growth arrest of senescent cells is triggered by transient p21 induction, while p16, appears to be responsible for maintaining the growth arrest after the decay of p21 (Alcorta et al., 1996, Proc. Natl. Acad. Sci. USA 93: 13742-13747).

-42p16 (in striking contrast to p21) is frequently mutated in human tumors (Hall Peters, 1996, Adv. Cancer Res. 68: 67-108), including HT1080 fibrosarcoma used in the present study. If the primary carcinogenic effect of pl6 mutations is abortive senescence, then cells expressing mutated pl6 would experience prolonged p21 induction. Consistent with the results disclosed herein, re-entry into the cell cycle under these conditions would be expected to result in the development of karyotypic abnormalities. Unlike pl6, p21 would act more as an oncogene than as a tumor suppressor in this process, which can explain the rarity of p21 mutations in cancer.

Thus, the invention provides methods for identifying compounds having an anticarcinogenic effect by inhibiting the downregulation of genes that control cell division upon the induction of CDK inhibitors. The compounds produced by these methods would be expected to be able to minimize the development of cells having karyotypic abnormalities, which in turn would be expected to reduce the likelihood that such cells would develop into malignant disease.

In addition, the Examples demonstrate that induced expression ofpl6 mimics the effects of p21 gene expression, and that the same genes whose expression is modulated by p21 gene expression are also modulated by p16 gene expression (see Figure 11).

Thus, the methods of the invention have been extended to include cells in which p16 gene expression is induced, either by induction of the endogenous p16 gene or in recombinant cells comprising an inducible expression construct encoding p16.

The invention also provides methods for identifying compounds that induce or promote senescence. In this aspect, the invention provides compounds that increase inhibition of genes inhibited by CDK inhibitor expression. Inhibition of cell division and cell cycle progression control genes is shown herein to prevent cells from re- -43entering the cell cycle after induction of CDK inhibitor expression and result in irreversible growth arrest. Thus, compounds that induce or potentiate CDK inhibitorinduced repression of such genes are effective in promoting cell senescence and terminal growth arrest. In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16. Thus, the invention provides methods for identifying compounds that inhibit cellular genes that control cell cycle progression, most preferably genes identified in Table I. In preferred embodiments, the compounds are used to promote senescence of mammalian cells, most preferably tumor cells, hyperplastic cells or any cell type that is pathological or disease-causing due to excessive proliferation. In preferred embodiments of this aspect of the invention, the methods comprise the steps of inducing CDK inhibitor expression in a mammalian cell in the presence or absence of the compound; assaying the cell for expression of genes repressed by the CDK inhibitor; and identifying the compound as a potentiator of senescence if the genes are repressed to a greater extent in the presence of the compound than in the absence of the compound.

In preferred embodiments of this aspect of the invention, the CDK inhibitor is p21 or p16. In other aspects of the methods of the invention, compounds that promote senescence in a mammalian cell are identified independently of CDK inhibitor-directed experimental manipulation, for example, by inducing senescence in the cells in any of the ways disclosed above. It is known in the art that senescence can be induced even in p21-deficient cells (Chang et al., 1999, Oncogene 18:.4808-4818 and Pantoja et al., 1999, Oncogene 18: 4974-4982) and that some senescence-inducing treatments, such as the treatment of MCF-7 cells with all-trans retinoic acid (Chang et al., 1999, Cancer Res. 59: 3761-3767), are associated with a decrease rather than an increase in the cellular levels of p21 (Zhu et al., 1997, Exp. Cell Res. 234: 293-299). Similarly, several -44anticancer drugs or ionizing radiation can induce senescence in pl6-deficient cell lines, such as HT1080 fibrosarcoma or HCTI16 colon carcinoma (Chang et al., 1999, Oncogene 18: 4808-4818).

The invention also provides methods for potentiating senescence in a mammalian cell, comprising the step of contacting the cell with a compound identified by the methods of the invention. In preferred embodiments, the mammalian cells are tumor cells, hyperplastic cells or any cell type that is pathological or disease-causing due to excessive proliferation. In alternative embodiments, the methods comprise the additional step of contacting the cells *with radiation or anticancer, cytotoxic or antiproliferative drugs.

The observed effects of CDK inhibitor induction, particularly p21 and p16 induction on gene expression show numerous correlations with the changes that have been associated with cell senescence and organism aging. Some of these correlations come from the analysis of CDK inhibitor-inhibited genes. Thus, senescent fibroblasts were reported to express lower levels of Rb (Stein et al., 1999, Mol. Cell. Biol. 9: 2109- 2117), as we have also observed upon p21 induction. It is also interesting that three CDK inhibitor-inhibited genes, CHL1, CDC21 and RAD54 encode members of the helicase family. A deficiency in another protein of the helicase group has been identified as the cause of Werner syndrome, a clinical condition associated with premature aging and, at the cellular level, accelerated senescence of cells in culture (Gray et al., 1997, Nature Genet. 17: 100-103).

The strongest correlations with the senescent phenotype, however, come from identification of CDK inhibitor-induced genes, many of which are known to increase their levels during replicative senescence or organism aging. Overexpression of ECM proteins is a known hallmark of replicative senescence, and two CDK inhibitor-induced genes in this group, fibronectin 1 and plasminogen activator inhibitor 1 (PAI-1), have been frequently associated with cellular senescence (reviewed in Crisofalo Pignolo, 1996, Exp. Gerontol. 31: 111-123). Other CDK inhibitor-induced genes that were also reported to be overexpressed in senescent fibroblasts include tissue-type plasminogen activator (t-PA)(West et al., 1996, Exp. Gerontol. 31: 175-193), cathepsin B (diPaolo et al., 1992, Exp. Cell Res. 201: 500-505), integrin 03 (Hashimoto et al., 1997, Biochem.

Biophys. Res. Commun. 240: 88-92) and APP (Adler et al., 1991, Proc. Natl. Acad. Sci.

USA 88: 16-20). Expression of several CDK inhibitor-induced proteins was shown to correlate with organism aging, including t-PA and PAI-I (Hashimoto et al., 1987, Thromb. Res. 46: 625-633), cathepsin B (Bernstein et al., 1990, Brain Res. Bull. 24: 43- 549) activin A (Loria et al., 1998, Eur. J. Endocrinol. 139: 487-492), prosaposin (Mathur et al., 1994, Biochem. Mol. Biol. Int. 34: 1063-1071), APP (Ogomori et al., 1988, J. Gerontol. 43: B157-B162), SAA (Rosenthal Franklin, 1975, J. Clin. Invest.

55: 746-753) and t-TGase (Singhal et al., 1997, J. Investig. Med. 45: 567-575).

The most commonly used marker of cell senescence is the SA-P-gal activity (Dimri et al., 1995, Proc. Natl. Acad. Sci. USA 92: 9363-9367). This gene is strongly elevated in IPTG-treated p21-9 cells (Chang et al., 1999, Oncogene 18: 4808-4818).

SA-1-gal was suggested to represent increased activity and altered localization of the 2 0 lysosomal p-galactosidase (Dimri et al., 1995, ibid.), and other studies have described elevated lysosome activities in senescent cells (Cristofalo Kabakijan, 1975, Mech.

Aging Dev. 4: 19-28). Five lysosomal enzymes appear in Table II, including Nacetylgalactosamine-6- sulfate sulfatase (GALNS), cathepsin B, acid a-glucosidase, acid lipase A and lysomal pepstatin-insensitive protease. p21 also upregulated genes for -46mitochondrial proteins SOD2, metazin and 2, 4-dienoyl-CoA reductase, which correlates with reports of different mitochondrial genes overexpresssed in senescent cells (Doggett et al., 1992, Mech. Aging Dev. 65: 239-255; Kodama et al., 1995, Exp. Cell Res. 219: 82-86; Kumazaki et al., 1998, Mech. Aging Dev. 101: 91-99).

As disclosed in the following Examples, there are many similarities between the effects of p21 induction in p21-9 cells and changes associated with senescence in normal fibroblasts. Senescent cells, in particular, were shown to overproduce different growth factors and ECM proteins that may promote metastasis (Campisi et al., 1998, J. Investig.

Dermatol. Symp. Proc. 3: Several growth factors and growth factor receptors have also been identified among the genes that are induced by irradiation in a p53-dependent manner, under the conditions of strong p21 induction (Komarova et al., 1998, Oncogene 17: 1089-1096). Interestingly, most of these genes did not contain p53-binding sites in their promoters. Our results suggest that induction of growth factors by p53 may be an indirect effect, mediated through p21 induction.

Thus, the invention provides methods for identifying genes associated with cellular senescence, particularly genes that are induced during senescence, and particularly by CDK inhibitor expression. The invention also provides methods for identifying compounds that can inhibit CDK inhibitor-mediated induction of such genes.

Such compounds would be expected to exhibit the capacity to reduce, repress or reverse cellular senescence by their effects on CDK inhibitor-mediated induction of gene expression.

Strikingly, products of many genes that we found to be induced by both pl 6 and p21 have been linked to age-related diseases, including Alzheimer's disease, amyloidosis, atherosclerosis and arthritis. Thus, APP gives rise to P-amyloid peptide, -47the main component of Alzheimer's amyloid plaques. Complement C3 (Veerhuis et al., 1995, Virchows Arch. 426: 603-610) and AMP deaminase (Sims et al., 1998, Neurobiol.

Aging 19: 385-391) were also suggested to play a role in Alzheimer's disease. It is especially interesting that t-TGase, which is most rapidly induced by p21 and which has been described as a pleiotropic mediator of cell differentiation, carcinogenesis, apoptosis and aging (Park etal., 1999, J. Gerontol. A Biol. Sci. 54: B78-B83), is involved in the formation of plaques associated with both Alzheimer's disease and amyloidosis (Dudek Johnson, 1994, Brain Res. 651: 129-133). The latter disease is due to the deposition of another CDK inhibitor-induced gene product, SAA, which has also been implicated in atherosclerosis, osteoarthritis and rheumatoid arthritis (Jensen Whitehead, 1998, Biochem. J. 334: 489-503). Two other CDK inhibitor upregulated secreted proteins, connective tissue growth factor (CTGF) and galectin 3 are involved in atherosclerosis (Oemar et al., 1997, Circulation 95: 831-839; Nachtigal et al., 1998, Am. J. Pathol. 152: 1199-1208). In addition, cathepsin B (Howie et al., 1985, J. Pathol. 145: 307-314), PAI-1 (Cerinic et al., 1998, Life Sci. 63:-441-453), fibronectin (Chevalier, 1993, Semin.

Arthritis Rheum. 22: 307-318), GALNS and Mac-2 binding protein (Seki et al., 1998, Arthritis Rheum. 41: 1356-1364) have been associated with osteoarthritis and/or rheumatoid arthritis. Furthermore, senescence-related changes in ECM proteins, such as increased PAI-1 expression, were proposed to result in age-specific deterioration in the structure of skin and other tissues (Campisi, 1998, J. Investig. Dermatol. Symp. Proc. 3: Increased fibronectin production by aging cells was also suggested to increase the density of the fibronectin network in ECM, which may contribute to slower would healing in aged individuals (Albini et al., 1988, Coll. Relat. Res. 8: 23-37).

The results disclosed herein indicate that CDK inhibitor induction affects cellular -48gene expression in a way that may increase the probability of the development of cancer or age-related diseases. A surge of CDK inhibitorexpression occurs not only in normal replicative senescence but also in response to cellular damage; in both cases, the undesirable effects of CDK inhibitor induction would be expected to accumulate in an age-dependent manner. Elucidation of specific molecular interactions and regulatory pathways that are responsible for these effects of CDK inhibitors such as p 16 and p21 on gene expression may suggest new approaches to the prevention of cancer and age-related diseases.

Thus, the invention provides methods for identifying genes associated with agerelated diseases. The invention also provides methods for identifying compounds that can inhibit CDK inhibitor-mediated induction of such genes. Such compounds would be expected to exhibit therapeutic capacity to prevent, retard or reverse age-related diseases.

The methods of the invention directed towards identifying genes whose expression is modulated by CDK inhibitorstake advantage of the ability to experimentally induce CDK inhibitor expression. Cells as provided by the invention containing inducible CDK inhibitor genes, such as p16 and p 2 1 genes that can be used to isolate cellular mRNA reflecting the expression status of genes induced, repressed and unchanged by CDK inhibitor expression. Naive cells in which CDK inhibitor expressionis not induced provide a comparative, control source of cellular mRNA. A plurality of nucleic acids, most preferably cDNA copies of cellular mRNA, can be obtained that is specific for either induced or repressed genes by constructing differential cDNA libraries using subtractive hybridization methods. See, for example, Diatchenko et al., 1996, Proc. Natl. Acad. Sci. USA 93: 6025-6030. mRNA or cDNA isolated before -49and after CDK inhibitor induction can also be used as probes for hybridization analysis, either using arrayed or non-arrayed cDNA libraries, and differentially-expressed genes can be identified from such hybridization. See, generally, Sambrook et al., 1990, MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press: New York. Alternatively, differential display of the subtracted cDNA population can be performed to yield sets of genes that are either upregulated or downregulated by CDK inhibitor expression.

In additional embodiments, genes that are upregulated or downregulated by CDK inhibitorexpression can be isolated using molecular cloning techniques well known in the art. Sambrook et al., ibid. Differential cDNA libraries produced as described above can be screened with probes specific for genes induced or repressed by, for example, p16 or p21, using subtractive hybridization methods that enrich the probes for the appropriate cDNA population. Alternatively, such probes can be used to screen conventionally-prepared cDNA libraries constructed to maximize the percentage of colonies comprising full-length or close to full length cDNAs, to facilitate cloning of CDK inhibitor-modulated genes, particularly novel genes identified using the methods of the invention. Said genes are also intended to fall within the scope of this invention.

The following Examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature.

EXAMPLE 1 Production of a Mammalian Cell comprising an Inducible p21 Gene A recombinant derivative of human fibrosarcoma cell line HT1080, p21-9, was produced essentially according to Chang et al. (1999, Oncogene 18: 4808-4818, incorporated by reference herein). This cell line contained a p21 coding sequence under the transcriptional control of a promoter regulated by isopropyl-p-thiogalactoside (IPTG). Expression of p21 can be induced by culturing these cells in the presence of a sufficient amount of IPTG, thereby permitting the sequellae of p21 expression to be studied in the absence of any additional effects that induction of the endogenous p21 gene might provoke. This cell line has been deposited on April 6, 2000 in the American Type Culture Collection Manassas, VA and given Accession Number PTA 1664.

Briefly, a subline ofHT1080 expressing a murine ecotropic retrovirus receptor and a modified bacterial lacI repressor encoded by the plasmid 3'SS (Stratagene) (described in Chang Roninson, 1996, Gene 33: 703-709, incorporated by reference) was infected with retroviral particles containing recombinant retrovirus LNp21C03, the structure of which is shown in Figure 1. This retroviral vector contains the bacterial neomycin resistance gene (neo) under the transcriptional control of the retroviral long terminal repeat promoter, p21-encoding sequences are cloned in the opposite orientation to the transcriptional direction of the neo gene, and under the control of a modified human cytomegalovirus promoter. Specifically, the CMV promoter contains a threefold repeat of bacterial lac operator sequences that make expression from the promoter sensitive to the lacl repressor expressed in the cell. LNp21C03 was constructed by cloning a 492bp fragment of DNA comprising the p21 coding sequence into the Notl and BgII sites of the parent vector, LNXCO3 (disclosed in Chang Roninson, ibid.).

After infection, cells infected with the LNp21CO3X vector were selected by culturing the cells in the presence of 400gtg/mL G418 (obtained from BRL-GIBCO, Gaithersburg, MD). Clonal line p 2 1 -9 was derived from LNp21 C03 transduced, G418- -51 resistant cell lines by end-point dilution until a clonal cell line was obtained.

EXAMPLE 2 Cell Growth Assays p21-9 cells produced as described in Example 1 were used in cell growth assays to determine what changes in cell growth occurred when p21 was expressed in the cell.

p21 expression from the LNp21CO3 vector in p21-9 cells was induced by culturing the cells in DMEM medium containing 10% fetal calf serum (Hyclone, Logan, UT) and IPTG. Results of these assays are shown in Figures 2A and 2B. Figure 2A shows the time course of p 2 1 protein production in cells cultured in the presence of IPTG. p21 gene expression increased between 6 and 12 hours after introduction of IPTG into the growth media, which expression peaked at about 24 hours postinduction. Upon removing the cells from IPTG-containing media, p21 expression fell about as rapidly as it had risen, returning to pre-induction levels at about 24 hours after IPTG was removed, (Figure 2B).

Cell growth in the presence of IPTG was assayed in three ways: measuring 3

H-

thymidine incorporation (termed the "labeling index"); observing the number of mitotic cells in the culture by microscopy (termed the "mitotic index") and determining the distribution of the culture cells in different portions of the cell cycle (termed the "cell cycle distribution"). These results are shown in Figures 3A through 3C.

3H-thymidine incorporation assays were performed substantially as described by Dimri et al. (1995, Proc. Natl. Acad. Sci. USA 92: 9363-9367). Cells were cultured in the presence of 'H-thymidine for 3h, and then analyzed by autoradiography. DNA replication was determined by autoradiography ceased entirely by 9 hours after addition -52of IPTG to the culture media (Figure 3A). The mitotic index was determined by observing cells microscopically and calculating the number of cells in mitosis after staining with p5.g/mL 4,6-diamino-2-phenylindole (DAPI), and images were collected using a Leica DMIRB fluorescence microscope and Vaytek (Fairfield, Iowa) imaging system. Microscopically-detectable mitotic cells disappeared from these cultures in the presence of IPTG in two stages: the first occurring between 0-4 hours after IPTG addition (wherein the mitotic index dropped from about 15% in untreated cells to about in IPTG-treated cells) and then again between about 10-14 hours after IPTG addition (wherein the mitotic index dropped to zero at about 13 hours after IPTG addition (Figure 3B).

Cell cycle distribution was determined using FACS analysis of DNA content after staining with propidium iodide as described by Jordan et al. (1996, Cancer Res. 56: 816-825) using Becton Dickinson FACSort. Cell cycle distribution stabilized after 24 hrs of IPTG treatment (shown in Figure 3C). By this time, 42-43% of IPTG-treated cells were arrested in GI and G2, respectively, and about 15% of the cells were arrested with S-phase DNA content.

The effects of p21 expression were also investigated by releasing cells from the effects of p21 by removing IPTG from the cell culture media. It was known that IPTGtreated p21-9 cells displayed morphological senescence markers (Chang et al., 1999, ibid.). As shown in Figure 2B, p21 gene expression levels in p 2 1-9 cells reverted to basal levels within 24 hours after removal of IPTG. Here, it was determined whether IPTG-treated p21-9 cells show any loss of clonogenic capacity after removal of IPTG.

The results of these experiments are shown in Figures 4A through 4D.

Colony assays for recovery from IPTG treatment were performed by plating -53 about 2,000 p 2 1 -9 cells per 10cm culture dish in DMEM/ 10% FCS and the presence or absence of IPTG. Cells were allowed to form colonies for 10 days before their clonogenic capacity was determined. p21-9 cells were treated with three concentrations of IPTG: 0.5jM, 5pM and 50pM. These treatments induced, respectively, no measurable increase over basal p21 levels (0.5gtM), half-maximal (5gM) or maximal increase (50uM) in p21 gene expression. As shown in Figure 4A, treatment of p21-9 cells with 0.5 1 M IPTG did not inhibit colony formation. In contrast, continuous exposure of the cells to 51M or 50uM IPTG reduced the clonogenicity of p21-9 cells by and 100%, respectively. When IPTG was removed after 12 or 14 hours, cells treated with 5utM IPTG showed substantially undiminished colony formation. However, the 50pM IPTG-treated cells showed a decrease in clonogenicity of 58-63%. After days treatment, cells cultured in 5gM IPTG showed a decreased clonogenicity of 58%, and cells cultured in 50pM IPTG showed a decreased clonogenicity of 95-99%.

These results indicated that the ability of cells to recover after p21 gene expression decayed was inversely correlated with the level of induced p21 and with the duration of p21 induction. This result was consistent with results obtained by others in other cell culture systems (Fang et al., 1999, Oncogene 18: 2789-2797).

The causes of the loss of clonogenicity were investigated as follows.

Resumption of DNA replication was first detected about 20 hours after release from IPTG using the 3 H-thymidine incorporation assay as described above. These results are shown in Figure 4B. Resumption of mitosis in these cells was first detected about hours after IPTG release, as determined from the mitotic index as described above.

These results are shown in Figure 4C. The percentages of cells entering the S or M phase of the cell cycle were higher in cells that were treated with IPTG for one day than -54for five days (compare the curves for each in Figures 4B and 4C) but the differences were not significant enough to account for the corresponding difference in clonogenic recovery as shown in Figure 4A.

Microscopic examination of culture plates from the clonogenic assays showed that plates treated with 50.LM IPTG for three or more days contained numerous single cells and small cell clusters that failed to develop into colonies. In addition, release from IPTG was associated with the appearance of floating cells during the first two days after IPTG release, and the number of such cells was much higher when cells were released after three days of IPTG induction than after one day (as shown in Figure 4D). Most of these floating cells were dead, as indicated by trypan blue staining and a 100- to 1,000fold decrease in clonogenicity The effect of p21 induction in these cells was further studied by examining the DNA content of growth-retarded and dead cells that appeared after release from prolonged IPTG treatment. Growth-retarded cells were isolated using FACS on the basis of increased retention of PKH2, a lipophilic fluorophore that stably incorporates into the cell membrane and is evenly divided between daughter cells; this leads to a proportional decrease in cellular fluorescence with each round of cell division, and no decrease in non-dividing or dead cells (Horan Slezak, 1989, Nature 340: 167-168).

These assays were performed as described in Chang et al. (1999, Cancer Res. 59: 3761- 3767). Untreated p21-9 cells and cells treated with 50g.m IPTG for five days were labeled with PKH2, plated in IPTG-free medium, and their PKH2 fluorescence was analyzed on consecutive days. As shown in Fig. 5A, IPTG-treated cells started dividing later than the control cells and developed a heterogeneous PKH2 profile, with an emerging peak of proliferating cells and a shoulder of growth-retarded cells with high PKH2 fluorescence. The growth-retarded cells also showed elevated side scatter that is characteristic for senescent cells (Chang et al., 1999, ibid.). The proliferating (PKH2oSS') and growth-retarded (PKH2"'SS"') cell populations were separated by FACS six days after release from IPTG, and their DNA content was analyzed by PI staining. The growth-retarded fraction differed from the proliferating cells in having a higher G2/M fraction and a large number of cells with greater than 4C DNA content (shown in Fig. 5B). The polyploid nature of the latter cells was confirmed by fluorescence in situ hybridization (FISH) of interphase nuclei with specific probes for chromosomes 18 and 21; these experiments were performed as described in Chang et al.

(1999, ibid.). High polyploid and G2/M fractions were also observed among floating dead cells collected after release from IPTG (shown in Fig. 5C); microscopic analysis indicated that many of these dead cells were in mitosis.

To investigate the origin of polyploid cells, the time course of changes in DNA content of the entire cell population after release from IPTG was determined. The number of polyploid cells greatly increased 24-28 hrs after release (as shown in Fig.

concurrently with the resumption of DNA synthesis (compare, Fig. 4B). This result indicated that many of the released cells were undergoing endoreduplication, an unscheduled round of DNA replication. The time course and magnitude of endoreduplication were very similar, however, between cells released after one day (Fig.

5D) or after 3-5 days of IPTG inhibition.

A major difference between cells that were inhibited by IPTG for one day compared with those inhibited for 5 days emerged, however, when the morphology of attached mitotic cells arising 1-2 days after release from IPTG was examined. These results are shown in Figure 6. While an overwhelming majority of mitotic figures in -56untreated cells appeared morphologically normal (Fig. 6, left), most of the mitotic figures in cells released after IPTG treatment showed numerous abnormalities, including multicentric mitosis, uneven chromosome distribution and prophase arrest (Fig. 6, right).

The percentage of normal mitoses in 1-day and 5-day IPTG treated cells were 45% and respectively, which is close to the corresponding values for clonogenic recovery (38% and These results suggest that abnormal mitosis, together with endoreduplication, are responsible for the loss of clonogenicity after release from p 2 1.

These results indicated that induced expression of p21 has profound effects not only on the cells while the gene is expressed, but effects that linger and interfere with normal recovery of the cells into the cell cycle and growth.

EXAMPLE 3 Analysis of Gene Expression Modulated by p21 Gene Expression The results disclosed in Example 2 suggested that the morphological and cell cycle consequences of p21 induction could be the result of repression of genes that control cell cycle progression. The effects of p21 induction on cellular gene expression were examined as follows.

Reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed to investigate expression of genes known to be involved in the control of cell cycle checkpoint progression. Preliminary RT-PCR analysis of 27 genes involved in cell cycle control and DNA replication revealed that eight of these genes were inhibited by IPTG in p21-9 cells. Total RNA was extracted from p21-9 cells collected at different time points during IPTG treatment and release. RT-PCR analysis of changes in gene expression for downregulated genes was carried out essentially as described by Noonan -57 et al. (1990, Proc. Natl. Acad. Sci. USA 87: 7160-7164).

A more comprehensive analysis was performed by isolating poly(A) RNA from untreated p21-9 cells and from cells that were treated for 3 days with 50 Lm IPTG.

cDNA was prepared from the poly(A) RNA and used as probes for differential hybridization with the Human UniGEM V cDNA microarray (as performed by Genome Systems, Inc., St. Louis, MO), which contains over 4,000 sequence-verified known human genes and 3,000 ESTs. More than 2,500 genes and ESTs showed measurable hybridization signals with probes from both untreated and IPTG-treated p21-9 cells.

Genes that were downregulated with balanced differential expression >2.5 or upregulated with balanced differential expression >2.0 are listed in Tables I and II, respectively.

Expression of 69 of these genes was individually tested by RT-PCR or northern hybridization with probes derived from inserts of the cDNA clones present in the microarray; these cDNAs were obtained from Genome Systems, Inc. In addition, enzyme-linked immunosorbent assay (ELISA) measurement of p21 protein was carried out using WAFI ELISA kit (obtained from Oncogene Science, Uniondale, NY) as described (Chang et al., 1999, Oncogene 18: 4808-4818). The following primary antibodies were used for immunoblotting: mouse monoclonal antibodies against Cdc2 (Santa Cruz), cyclin A (NeoMarkers), Plk 1 (Zymed) and Rb (PharMingen); rabbit polyclonal antibodies against MAD2 (BadCo), p107 (Santa Cruz), CTGF (Fisp-12; a gift of Dr. L. Lau), Prc 1 (a gift of Drs. W. Jiang and T. Hunter), and topoisomerase lla (Ab0284; a gift of Dr. W.T. Beck), and sheep polyclonal antibody against SOD2 (Calbiochem). Horse radish peroxidase (HRP)-conjugated secondary antibodies used were goat anti-mouse and goat anti-rabbit IgG (Santa Cruz) and rabbit anti-sheep IgG -58 (KPL). Protein concentrations in all samples were equalized after measurement with BioRad protein assay kit. Immunoblotting was carried out by standard procedures, and the signal was detected by chemiluminescence using LumiGlo (KPL).

These results are shown in Figures 7A through 7C. The changes in gene expression predicted by the microarray assays described above were confirmed for 38/39 downregulated and 27/30 upregulated genes. The observed signal differences in northern hybridization or RT-PCR for most of the tested genes (Figure 7A through 7C) appeared to be higher than the values of balanced differential expression determined from the cDNA array (Tables I and II), suggesting that cDNA array hybridization tends to underestimate the magnitude of p21 effects on gene expression. Changes in the expression of 6 downregulated and 4 upregulated genes were also tested at the protein level by immunoblotting (Figure 7B) or zymography (not shown) and were confirmed in all cases tested.

It was recognized that p21-mediated changes in gene expression were comprised of near-term effects and longer-term effects that followed p21-induced cell growth arrest. For this purpose, the time course of changes in the RNA levels of a subset of p21-inhibited (Fig. 7B) and p21-induced genes (Fig. 7C) after the addition and removal of IPTG was determined. Immunoblotting was used to analyze the time course of p21induced changes in Rb phosphorylation (as indicated by electrophoretic mobility) and in the cellular levels of Rb and several proteins that were inhibited by p21 according to the cDNA array; these results are shown in Figure 7B. Rb was found to become dephosphorylated as early as 6 hrs after the addition of IPTG. Furthermore, Rb protein levels decreased sharply between 12-24 hrs (shown in Figure 7B), but no significant changes were detected in RB mRNA levels (data not shown). A similar decrease was -59observed for a Rb-related protein p107 (shown in Fig. 7A).

1. Gene expression inhibited by p21.

All the tested p21-inhibited genes showed a rapid response to p21 induction and release. Five of these genes (topoisomerase IIa, ORC PLKI, PRCI and XRCC9) showed significant inhibition at both RNA and protein levels between 4 and 8 hrs after the addition ofIPTG (Fig. 7B). This pattern has been termed an "immediate response," which parallels the kinetics of cell growth arrest and Rb dephosphorylation. Other p21inhibited genes (such as CDC2 or DHFR) showed an "early response" pattern that lags slightly behind the cessation of DNA replication and mitosis, with a major decrease in mRNA levels detectable only 12 hrs after the addition of IPTG. All p21-inhibited genes, however, resumed their expression 12-16 hrs after the removal of IPTG, when the cells were still growth-arrested and before the resumption of DNA replication and mitosis (Fig. 7B). This analysis indicated that changes in the expression of p21 -inhibited genes were near-term effects of p21 induction and release and were not a consequence of cell growth arrest and recovery.

In summary, 69 genes and 3 ESTs were identified by the cDNA microarray as downregulated in p21-induced cells, with balanced differential expression of 2.5-12.6 (Table 1A); 5 additional genes identified by our earlier assays as downregulated in IPTG-treated cells are listed in Table IB. A strikingly high fraction of downregulated genes identified by the cDNA array (43 of 69) were associated with mitosis, DNA replication, segregation and repair and chromatin assembly, indicating a highly selective nature of p21-mediated inhibition of gene expression.

The largest group of p2 -downregulated genes are that have been implicated in the signaling, execution and control of mitosis. These genes include CDC2 and cyclin B 1 that form the mitosis-initiating complex, polo-like kinase (PLKI) that plays a role in the onset of mitosis, mitotic checkpoint control and cytokinesis (Glover et al., 1998, Genes Develop. 12: 3777-3787) and CDC2-interacting protein CKsHsl, a target of mitotic checkpoint control (Hixon et al., 1998, Mol. Cell Biol. 18: 6224-37). Other genes in this group encode a homolog of Xenopus condensin protein XCAP-H, a homolog of Rad21 repair protein involved in sister chromatid cohesion (Losada et al., 1998, Genes Develop. 2: 1986-1997) and mitotic recombination (McKay et al., 1996, Genomics 36: 305-315), a centrosome-associated kinase AIK1 involved in spindle formation (Kimura et al., 1997, J. Biol. Chem. 272: 13766-13771), centromere proteins CENP-A and CENP-F, as well as MAD2 and BUBR1 proteins that play a central role in the spindle checkpoint control (Li and Benezra, 1996, Science 274:246-248; Chan et al., 1999, J. Cell Biol. 146: 941-954), mitotic centromere-associated kinesin (MCAK), kinesin-like protein HSET located at the interphase centrosome and mitotic spindle, CHL1 helicase (a homolog of a yeast protein that plays a role in proper chromosome distribution during mitosis; Gerring et al., 1990, EMBO J. 9: 4347-4358), and three proteins involved in cytokinesis, Prcl, Aiml/Aik2 and citron kinase (Jiang et al., 1998, Mol. Cell2: 877-885; Terada et al., 1998, EMBOJ. 17: 667-676; Madaule et al., 1988, 2 0 Nature 394: 491-494). p 2 1 also inhibits genes that encode nuclear envelope proteins lamin B and lamin B2, lamin-associated polypeptides a (thymopoietin a) involved in nuclear assembly, and M-phase phosphoproteins MPP2 and MPP5. Deficiencies in many of the above proteins are known to result in abnormal chromosome segregation -61 and polyploidization, the same events that we observed in p21-9 cells after release from

IPTG.

Many p21-inhibited genes are involved in DNA replication and segregation, chromatin assembly and DNA repair. Some of these genes encode enzymes involved in nucleotide biosynthesis, including ribonucleotide reductase subunits MI and M2, thymidine kinase, thymidylate synthase, uridine phosphorylase and dihydrofolate reductase. Other proteins are involved in DNA replication, including components of the replication licensing factor Cdc47/Mcm4, Cdc45 homolog, Orcl protein of the origin recognition complex, DNA polymerase a, B-Myb, 37-kD subunit of replication factor C, and DNA ligase I. This group also includes genes involved in the segregation of replicated DNA (topoisomerase IIH), inheritance of epigenetically determined chromosomal states (p60 subunit of chromatin assembly factor-I), and other chromatin components, such as high mobility group proteins 1 and 2. Several p21-inhibited genes are associated with DNA repair, including XRCC9, which may be involved in DNA post-replication repair or cell cycle checkpoint control (deWinter et al., 1998, Nat Genet.

281-283), Rad54 recombination repair protein, exonuclease Hexl/Rad2, and the above Rad21 homolog and DNA ligase I.

Over 60% of p21-inhibited genes in the cDNA array are involved in mitosis, DNA replication, segregation and repair. Such biological selectivity is unprecedented in large-scale expression profiling studies. A corollary to this observation is that p21inhibited genes whose function is presently unknown are likely to play a role in cell cycle progression. Indeed, six p21-inhibited genes were originally listed in the cDNA array as ESTs or genes with unknown function, but a database search has linked three of their products to cell division of DNA repair. In one case, the originally identified EST -62was found to map in a genomic clone 3' to the coding sequence of citron kinase; inhibition of the citron kinase gene by p21 was then demonstrated by RT-PCR based on its coding sequence. Cloning of additional p21-inhibited genes is likely to yield novel genes that play a role in mammalian cell division.

These results also suggest further opportunities for discovering components of the cellular program of p21-induced senescence that would be targets for therapeutic intervention. It has been suggested that p21-mediated inhibition of gene expression is a result of E2F inhibition (de Toledo et al., 1998, Cell Growth Differ. 9: 887-896). In agreement with this interpretation, a subset of our p21-inhibited genes CDC2, ORC 1, DHFR, cyclin Al) contain E2F sites in their promoters. On the other hand, no E2F sites could be found in the promoters of some p21-inhibited genes cyclin B 1), and some E2F-dependent genes cyclin E) were unaffected by p21 induction (data not shown). Some as yet unidentified regulatory factors, in addition to E2F, may therefore be involved in p21-mediated inhibition of gene expression. Such additional factors represent targets for novel pharmaceuticals, the existence and identity of said targets being available for elucidation using the methods and reagents provided by the instant invention.

2. Gene expression induced by p21 In addition to genes repressed by p21 expression, the assays described above detected genes induced by p21. The pattern of gene expression of p21 -induced genes is shown in Figure 7C. In contrast to p21-inhibited genes, p21-upregulated genes increased their expression only 48 hrs after the addition of IPTG, i.e. after the onset of growth arrest in all cells. Only one tested gene, tissue transglutaminase (t-TGase), -63showed a detectable increase 12 hrs after the addition of IPTG, but its expression reached a maximum only by 48 hrs (as shown in Fig.7C). Furthermore, elevated expression of all the tested genes (except for t-TGase) persisted for at least three days after release from IPTG, well after resumption of the cell cycle (not shown). This "late response" kinetics indicated that p21 induction of such genes was a delayed effect relative to p21-mediated growth arrest.

48 known genes and 6 ESTs or genes with unknown functions were identified as upregulated in p21-induced cells, with balanced differential expression of 2.0-7.8 (Table II). A very high fraction (20/48) of identifiable genes in this group encode extracellular matrix (ECM) components fibronectin 1, laminin a2, Mac-2 binding protein), other secreted proteins activin A, connective tissue growth factor, serum amyloid or ECM receptors (such as integrin 13). Several of these secreted proteins, as well as a large group of p21 -induced intracellular proteins (Table II), are known to be induced in different forms of stress response or to play a role in stress-associated signal transduction. Remarkably, many genes that we found to be induced by p21 are also upregulated in cellular senescence, organism aging, or different age-related diseases.

In contrast to p21 -inhibited genes, none of the genes found to be induced by p21 have any known functions that may trigger cell growth arrest. Furthermore, the induction of such genes is a late response that lags far behind the onset of growth arrest.

Interestingly, several p21-induced genes are positively regulated by NFKB, including superoxide dismutase 2 (SOD2) (Jones et al., 1997, Mol. Cell. Biol. 11: 6970-6981), t- TGase (Mirza et al., 1997, Amer. J. Physiol. 272: G281-G288), Alzheimer's P-amyloid precursor protein (APP) (Grilli et al., 1996, J. Biol. Chem. 271: 15002-15007) and the inflammatory protein serum amyloid A (SAA) (Jensen and Whitehead, 1998, Biochem J.

-64- 334: 489-503). Since p21 activates NFKB-dependent transcription through its effect on the transcription cofactor p300 (Perkins et al., 1997, Science 275: 523-527), it is possible that activation of p300 or related transcription cofactors may be responsible for the effect of p21 on some of the upregulatedgenes. The delayed kinetics of p21-mediated induction of gene expression suggest, however, that this induction occurs far downstream of the immediate effects of p21.

These results, and the nature of the genes set forth in Table II, indicate that expression of these genes is not involved in the growth arrest function of p21. However, the abundance of secreted proteins that we found among the products of p21-activated genes has important physiological consequences. As disclosed in Example 5 below, conditioned media from p21-induced cells exhibits two biological effects predicted by the nature of p21-upregulated genes: stimulation of cell growth and suppression of apoptosis. This finding, taken with the above discussed genetic destabilization in p21induced cells, suggests that "paracrine" effects of p21 may contribute to carcinogenesis through a tumor-promoting effect on neighboring cells. This raises the possibility that suppression of p21-mediated gene induction may provide a way to achieve an anticarcinogenic effect, and that p21-mediated gene induction pathways are targets of rational drug design for a new generation of cancer-preventing drugs.

The observed paracrine, anti-apoptotic effect of p21 induction agrees with the reported activities of prosaposin and galectin-3, secreted proteins that we found to be induced by p21 (Table II). Anti-apoptotic activity has also been associated with p 2 1 induced intracellular proteins SOD2 (Manna et al., 1998, J Biol. Chem. 273: 13245- 13254) and R-Ras (Suzuki et al., 1998, FEBSLett. 437: 112-116). Paradoxically, p21induced t-TGase and cathepsin B (Singhal et al., 1997, J. Investig. Med. 45: 567-575) have been ascribed a pro-apoptotic function. There are conflicting reports in the literature regarding the effects of p21 on apoptosis. In some systems, p21 overexpression induced apoptosis (Prabhu et al., 1996, Clin. Cancer Res. 2: 1221-1229; Tsao et al., 1999, J. Virol. 73: 4983-4990), but in other studies p21 protected cells from apoptosis induced by several types of treatment (Gorospe et al., 1997, Oncogene 14: 929-935; Lu et al., 1998, Oncogene 16: 705-712; Bissonnette Hunting, 1998, Oncogene 16: 3461-3469). The results disclosed herein that p21 induces both antiapoptotic and pro-apoptotic genes may explain the contradictory reports on the effects of p21 on apoptosis.

EXAMPLE 4 Identifying the Specificity of p21 Induction by Comparing IPTG-treated and Serum-Starved p21-9 Cells The identity of p21-induced changes in cellular gene expression that are likely to be a consequence of cell growth arrest was determined as follows.

Growth arrest (quiescence) was induced in p21-9 cells by serum starvation produced by culturing the cells in serum-free media for 4 days. In serum-starved cells, unlike IPTG-treated p21-9 cells, the cells did not develop a senescent morphology and showed only very weak SA-P-gal expression. p21 levels in serum-starved cells were increased only about 2-fold, as opposed to the 15-20 fold increase seen in IPTG-treated cells. Fig. 7D shows RT-PCR analysis performed as described above of the expression of a group of p21-inhibited and p21-induced genes in p21-9 cells that were growtharrested after 4 days in serum-free media or 3 days in the presence of 50 RtM IPTG.

Genes that were completely inhibited in p21-9 cells when the culture media contained -66gM IPTG were also inhibited in serum-starved cells, but most of these genes were inhibited to a lesser extent than in IPTG-treated cells.

Genes whose expression is induced by p21 showed three distinct patterns. The first group are genes whose expression is induced as strongly in quiescent cells as in senescent cells. These include galectin-3, superoxide dismutase 2, complement C3 and prosaposin, indicating that their induction was a consequence of cell growth arrest or that such genes were exquisitely sensitive to slightly elevated p21 levels. The second group are genes that were up-regulated in quiescent cells but not as strongly as in senescent cells. These genes include fibronectin-1, Mac2 binding protein and the Alzheimer precursor protein serum amyloid A. The third group are genes that are not detectably induced in quiescent cells but are strongly induced in senescent cells. These genes include CTGF, plasminogen activator inhibitor 1, tissue transglutaminase or natural killer cell marker protein NK4, integrin beta 3 and activin A.

The difference between the response of certain genes to induction of quiescence by serum starvation and cellular senescence through IPTG-induced overexpression of p21 identified these genes as diagnostic markers of senescence. Furthermore, novel senescence markers can now be identified by comparing their expression between p21 expressing and quiescent cells.

EXAMPLE Production of Conditioned Media containing Mitogenic Factors and Mitogenic Activity Assays Several p21 -upregulated secreted proteins act as growth factors, including CTGF (Bradham et al., 1991, J. Cell Biol. 114: 1285-1294), activin A (Sakurai et al., 1994, J.

-67- Biol. Chem. 269: 14118-14122), epithelin/granulin (Shoyab et al., 1990, Proc. Natl.

Acad. Sci. USA 87: 7912-7916) and galectin-3 (Inohara et al., 1998, Exp Cell Res. 245: 294-302), and to a lesser extent clusterin (Koch-Brandt Morgans, 1996, Prog. Mol.

Subcell. Biol. 16: 130-149), prostacyclin-stimulating factor (PSF; Yamauchi et al., 1994, Biochem. J. 303: 591-598), vascular endothelial growth factor-C (VEGF-C; Joukov et al., 1996, EMBOJ. 15: 290-298), gelsolin (Ohtsu et al., 1997, EMBOJ. 16: 4650-4656) and tissue inhibitor of metalloproteinases-1 (TIMP-1; Hayakawa et al., 1992, FEBSLett.

298: 29-32). These results suggested that p21 induction may cause paracrine mitogenic effects. In addition, galectin-3 (Akahani et al., 1997, Cancer Res. 57: 5272-5276) and prosaposin (Hiraiwa et al., 1997, Proc. Natl. Acad. Sci. USA 94: 4778-4781) were shown to have anti-apoptotic activity. Conditioned media from IPTG-treated p 2 1 -9 cells was tested to investigate whether it would have an effect on cell growth and apoptosis.

In these experiments, conditioned media were prepared by plating 106 p21-9 cells per 15cm plate in the presence of DMEM/ 10% FCS. The next day, IPTG was added to a final concentration of 50M, and this media was replaced three days later with DMEM supplemented with 0.5% FCS and 50tM IPTG. Two days later (days 3-5 of IPTG treatment), this conditioned media was collected and stored at 4 0 C up to 15 days before use. Control media were prepared by adding IPTG-free DMEM/ 0.5% FCS to untreated cells grown to the same density as IPTG-treated cells and collecting the media two days thereafter.

The slow-growing human fibrosarcoma cell line HS 15.T was used to detect mitogenic activity in these conditioned media. For mitogenic activity assays, both types of conditioned media, as well as fresh media and 1:1 mixtures of conditioned media and fresh media were used to test mitogenic activity. In these experiments, the conditioned -68media were supplemented with 1% or 2% FCS. Briefly, HS 15.T cells were plated in 12-well plates at 15,000 cells per well. Two days later, these cells were cultured in different types of media. The cells were grown in conditioned media for 60hr, and the H-thymidine at a concentration of 3.13 tCi/mL was added and incubated for 24 hrs.

Cells were then collected and their 3 H-thymidine incorporation determined as described by Mosca et al. (1992, Mol. Cell. Biol. 12: 4375-4383).

The addition of IPTG to fresh media had no effect in this assay (not shown). As shown in Fig. 8A, there was no significant difference between cell growth in fresh media and in conditioned media from untreated p 2 1-9 cells. In contrast, conditioned media from IPTG-treated cells increased 'H-thymidine incorporation up to three-fold (Fig. 8A).

Growth stimulation ofHS 15.T by conditioned media from IPTG-treated cells was also detectable by methylene blue staining (data not shown).

The effect of this conditioned media.on apoptosis was also determined. These experiments used a mouse embryo fibroblast line C8, immortalized by E1A. This cell line is highly susceptible to apoptosis induced by different stimuli (Lowe et al., 1994, Science 266: 807-810; Nikiforov et al., 1996, Oncogene 13: 1709-1719), including serum starvation (Lowe et al., 1994, Proc. Natl. Acad. Sci. USA 91: 2026-2030).

Apoptosis was analyzed by plating 3 x 10 5 C8 cells per 6-cm plate, and replacing the media on the following day with fresh media supplemented with 0.4% serum or with conditioned media (no fresh serum added). DNA content analysis and DAPI staining were carried out after 24 hrs and 48 hrs, and relative cell numbers were measured by methylene blue staining (Perry et al., 1992, Mutat. Res. 276: 189-197) after 48 hrs in low-serum media.

The addition of low-serum fresh media or conditioned media from IPTG-treated -69or untreated cells rapidly induced apoptosis in C8 cells,as evidenced by cell detachment and apoptotic morphology detectable in the majority of cells after DAPI staining (not shown). Conditioned media from IPTG-treated cells, however, strongly increased cell survival relative to fresh media and conditioned media from untreated cells, as measured by methylene blue staining of cells that remained attached after 48 hrs (as shown in Figure 8B). The effect of the conditioned media from p21 -induced cells was even more apparent in FACS analysis of cellular DNA content, which was carried out on combined attached and floating C8 cells 24 hrs and 48 hrs after media change (Fig. 8B). Unlike many other cell lines, apoptosis of C8 cells produces only a few cells with decreased (sub-G amount of DNA, and it is characterized by selective disappearance of cells with G2/M DNA content (Nikiforov et al., 1996, ibid.). Serum-starved cells in conditioned media from IPTG-treated cells retained the G2/M fraction and showed cell cycle profiles that resembled control cells growing in serum-rich media (Fig. 8B). The addition of IPTG by itself had no effect on apoptosis in C8 cells (not shown). Thus, p21 induction in HT1080 cells results in the secretion of mitogenic and anti-apoptotic factors, as predicted by the nature of p21-unregulated genes.

EXAMPLE 6 Production of Recombinant Expression Constructs containing a Reporter Gene Expressed by a p21-responsive Promoter Promoter-reporter constructs were prepared from human PLK1, NK4 and SAA promoters as follows. Polymerase chain reaction (PCR) amplification of promoterspecific DNA was performed using genomic DNA from HT1080 p21-9 cells as the template. PCR was carried out using PfuTurbo DNA Polymerase (Stratagene) and primer sets listed in Table IIIa. The PCR conditions for each primer set are described in 70 Table IIIb. PCR products were obtained and cloned into the TOPO TA cloning vectors pCR2. 1/TOPO (for PLK1 and SAA) or pCRII/TOPO (for NK4). These constructs were verified by sequencing, and the Kpn I-Xho I fragments containing promoters in the correct orientation were then inserted into the Kpn I and Xho 1 sites in a luciferasereporter vector pGL2 basic (Promega, Madison, WI) using standard recombinant genetic techniques (Sambrook el al., ibid.).

Two separately-isolated plasmid clones of each promoter construct were tested for p21-regulation by transient transfection assay. Each promoter-luciferase construct was mixed with the pCMV-p-gal (Promega) plasmid in 1:1 ratio and introduced into HT1080 p21-9 cells by LIPOFECTAMINE 2000 (Life Technologies, Inc., Gaithersburg, MD). Six to eight hours later, media with or without 50jtM IPTG was added to transfected cells, and cell extracts were prepared from these cells 60-72 hours later and assayed for luciferase activity (Luciferase Assay System, Promega). P-galactosidase assays were used as a normalization control for transfection efficiency.

Figure 9 shows the results of these experiments. Upon p21-induction in transfected cells, expression from promoter constructs prepared from the p21-inhibited gene PLK 1 was reduced to 5-fold) and expression from promoter constructs prepared from the p21-induced genes NK4 and SAA was increased to 10-fold for NK4 and to 30-fold for SAA). These results indicated that p 2 1 up-regulates or down-regulates expression of these genes by regulating their promoters, and that promoter constructs of such genes can be used to assay for p21-mediated regulation of gene expression.

-71 Table Ilia. Primer sequences promoter Sense primer Antisense primer CCTGTAATCCCAGCATTTGG AGACCTCGATCCGAGCAGA PLK1 (SEQ ID No. 1) (SEQ ID No. 2) TGGAGCTAGAAGAGCCCGTAGG GCCAAAAGTTCAAGGAGCCAA NK4 (SEQ ID No. 3) (SEQ ID No. 4) SA CAGAGTTGCTGCTATGTCCACCA CACTCCTTGTGTGTCTCCTCAC (SEQ ID No. 5) C (SEQ ID No. 6) Table Illb. PCR conditions promoter Denaturation Annealing Extension Cycles Product size PLK1 940, 1 min 680, 1 min 720, 1 min 40 sec 32 990 bp NK4 940, 1 min 650, 1 min 720, 1 min 40 sec 32 877 bp SAA 940, 1 min 680, 1 min 720, 1 min 40 sec 32 1000 bp EXAMPLE 7 Production of a Mammalian Cell comprising an Inducible p16 Gene A mammalian cell line comprising an inducible p16 gene was produced generally as described in Example 1 for production of an inducible p21 containing cell line. A recombinant derivative of human HT1080 fibrosarcoma cell line containing a recombinant expression construct encoding the bacterial lacI gene and expressing a murine ecotropic retrovirus receptor (HT1080 3'SS6; Chang Roninson, 1996, Gene 183: 137-142) were used to make the inducible p16-containing cells. A DNA fragment containing a 471bp coding sequence of human p16 (as disclosed in U.S. Patent 5,889,169, incorporated by reference) was cloned into the IPTG-regulated retroviral vector LNXRO2 (Chang Roninson, 1996, Gene 183: 137-142). This retroviral vector 2 0 contains the bacterial neomycin resistance gene (neo) under the transcriptional control of the retroviral long terminal repeat promoter, permitting selection using G418 (BRL- -72- GIBCO). The resulting construct, designated LNp6RO2, is depicted schemaicaly in Figure 10. This construct was introduced into HT1080 3'SS cells using conventional retroviral infection methods. After infection, cells infected with the LNpl6RO2 vector were selected by culturing the cells in the presence of 400gg/mL G418 (obtained from BRL-GIBCO). The G418-selected population of LNpl6RO2 transduced cells was designated HT1080/LNp 6RO2. This cell population has been deposited on October 2000 in the American Type Culture Collection Manassas, VA and given Accession Number PTA-2580.

EXAMPLE 8 Cell Growth and Gene Expression Assays The HT1080 derivatives carrying a human p16 gene inducible with IPTG as described in Example 7 were used in cell growth and gene expression assays as follows.

Cells were grown in the presence and absence of 50fM IPTG over the course of 6 days and the number of cells in the culture determined by light scattering at 600nm.

These results are shown in Figure 11. Culturing these cells in the presence of IPTG, thus inducing p 6 gene expression, resulted in growth inhibition relative to cells grown in the absence of IPTG.

RNA was then obtained from these cells, cultured in the presence or absence of IPTG for three days. These RNA samples were then used in RT-PCR assays performed essentially as described above in Examples 3 and 6, except that p-actin rather than 3 2 -microglobulin was used for normalization. Nine genes shown above to be inhibited by p21 and eighteen genes shown above to be induced by p21 were analyzed -73 for the effects of pl6 gene expression induced by IPTG treatment of these cells. These results are shown in Figure 12. All the tested p21-inhibited genes were also inhibited by IPTG-induced expression of p16, and all the tested p21-induced genes were also induced by IPTG-induced p16 expression. The tested inhibited genes were genes involved in cell cycle progression, and the tested induced genes were genes involved in Alzheimer's disease, amyloidosis, arthritis, atherosclerosis and paracrine apoptotic and mitogenic effects as described above with regard to induced p21 expression. The results shown in Figure 12 also illustrate that p16 expression has no detected effect on p21 expression.

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims.

-74- Table I Genes dlownregulated by p21 induction A. p21-inhibited genes identified by UniGemn V array: Genes Associated with mitosis: CDC2 CKsHs1 (.CDC2 kinase) PLK1 (polo-like kinase) XCAP-H" condensin homolog CEN P-A (centromere protein A) CENP-F icentromere protein F) MAD2 BUBR1 MCAK (mitotic centromere-associated kinesin) HSET kinesin-like protein CHU1 helicase AIK-1 (aurorallPL 1-related kinase) AIM-I (AIK-2- aurora/I PL 1 -related kinase) PRC1 (protein regulating cytokinesis 1) Citron kinase Lamin 81 Lamin B2 LAP-2 (lamin-associated protein 2) MPP2 (M phase phosphoprotein 2) (M phase phosphoprotein 5) Accession No.

X05360 X54941 U01038 D38553 U 14518 U30872 U654 10 AF053306 U63743 AL02 1366 U75968 D84212 AF004022 AF044588 H 10809 L37747 M94362 U18271 U746 12 X98261 Balanced Diff.

Expr.

2.5 5.5 5.1 6 5.3 2.5 66 5.9 38 3.6 3.3 4.6 10.2 12.6.

2.7 7 2.7 4.6 3.7 3.7 Confirmea

RW

R

R.W

R

R

.9 R, WV

R

R

R

R

R

R

R V

R

R

R

Associated DNA !1phcawor. stfgrc;_,tion qr vtrnrmatin issernbly: Thymidine kinase 1 K02581 Thymidylate synthase X02308 Unidine phosphorylase X90858 Ribonucleotidle reductase M1 X59543 Ribonucleotide reductase M2 X59618 CDC47 homolog (MCM7) D557 16 CDC21 homolog (MCM4) X74794 C0C45 homolog (Porc-PI) AJ223728 HsORC1 (origin recognition complex 1) U40152 DNA polymerase a X06745 Replication factor C (3741D subunit) M87339 B-MYB X1 3293 HPVI6 El protein binding protein U96131 Topoisomerase Ila J04088 Chromatin assembly factor-I (p60 subunit) U20980 High-mobility group chromosomal protein 2 X62534 High-mobility group chromosomal protein 1 063874 Histone H2A.FIZ variant AA203494 Associated with DNA repair:U0i XRCC9 U01 RAD54 homolog X97795 HEMi 5'-3 exonuclease (RAD2 homolog) AF0228 ATP-dependent DNA ligase I M66 RAD2 1 homotog 038551 Table I Associated with~ transcniption and RNA processing: Putative transcription factor CAl 50 AF017789 2.8 Transcriptional coactivator ALY AF047002 3.3 WHSCIMMSET (SET domain protein) AA401245 2.9 NN8-4AG (SET domain protein) U50383 2.8 EZH-2 (enhancer of zeste homnolog 2) U61 145 2.8 PTB-associated splicing factor X70944 AU-rich element RNA-binding protein AUF1 U02019 2.8 U-snRNP-associated cyclophilin AF016371 2.8 Other genes: 3-phosphoglycerate dehydrogenase AF006043 4.8 1-type amino acid transporter, subunit LATI M80244 4.1 R Hyaluronan-mediated motility receptor U29343 4 Phorbolin I (PKC-inducible) U03891 3.9 binding family protein 013633 3.7 R HTRIP (TNF receptor component) U77845 3.6 NAD-dependent methylenetetrahydrofolate dehydrogenase X1 6396 3.4 Membrane glycoprotein 4F2 antigen heavy chain J02939 3.2 Mucin-like protein D79992 3.2 (differentially expressed in meningiomas) L19183 2.9 P52rIPK (regulator of interferon-induced protein kinase) AF007393 2.8 Putative phosphoserine aminotransferase AA192483 2.8 Glucose 6-phosphate translocase Y15409 2.7 Calcyclin binding protein AF057356 2.6 Omithine decarboxylase I X16277 2.6 R Trophinin assisting protein (tastin) U04810 Acuyl-coen~zyme A cholesterol acyltransferase 1934 Pinin/SDK3 Y10351 Genes with unknown function: EST AA975298 2.7 EST AA034414 EST AA482549 B. p21-inhibited genes Identified by RT-PCR.

Genes Accession No. UniGemV resulto Cyclin Al U66838 Is Cyclin 81 M25753 is NM 001789 A Dihydrofolate reductase Joa0140 ING1 NM.005537 A eAbbreviations: R, RT-PCR; W, western blotting "Abbreviations: IS, insufficient signal: A, absent from the array 76 Table 11 Genes upregulated by p21 induction Accession Balanced Diff Genes No Expr Confirmed bya Secreted proteins and proteins associated with extracellular matrix: Fibronectin 1 X02761 5.7 R Plasminogen activator inhibitor, type I M14083 3.7 R, N Plasminogen activator, tissue type M 15518 2.8 Z Laminin 132 X79683 2.1 Desmocollin 2albb X56807 Podocalyxin-like protein U97519 2 Activin A (inhibin 53A) J03634 2 R Galectin 3 (Mac-2) A8006780 2.4 N Mac-2 binding protein L13210 2 R.,N Prosaposin J03077 2.9 N CTGF (connective tissue growth factor) M92934 3.3 N Granulin/epithelin AF055008 2.1 N Cathepsin 8 L0.4288 2.4 N Tissue transglutaminase M55153 2.5 R, N, W P37NB (slit homolog) U32907 2. 1 Serum amyloid A protein precursor M26152 4 R, N, W Alzheimer's disease amyloid A4 protein precursor D87675 2 R, N Complement C3 precursor K02765 5.9 R, N Testican X73608 2.1 N Integnin 133 M35999 2.1 R, N Lysosoma; proteins: N-acetylgalactosamine-8-suifate sulatase U06088 2.3 N Acid alpha-glucosidase X55079 2.4 N Acid lipase A (cholesterol esterase) X76488 2.1 N Lysosomal pepstatin-insensitive protease (CLN2) AF01 7456 Mitochondnal proteins: Superoxide dismutase 2 X07834 3.5 R, N, W Metaxin J03060 3.4 2.4-dienoyl-CoA reductase U78302 2 Other genes associated with stress response and signal transduction: Ubiquitin-conjugating enzyme (UbcH8) AF031 141 2 Ubiquitin-specific protease 8 D29956 2 RTPICap43IDrgl/Ndrl (inducible by nickel, retinoids, D87953 homocysteine and EIR stress) C-i 93 muscle ankyrin-repeat nuclear protein (cytokine- X83703 3 inducible) LRP major vault protein associated with multidrug resistance X79882 2.2 N 1-arrestin related HHCPA78 homolog (upregulated by S73591 4.1 N vitamin 03) R-RAS M14949 2.4 RAS 13 small GTPase X75593 2.2 P66 SHC (ski oncogene) U73377 '2 N MK-STYX (MAP kinase phosphatase-like protein) N75168 2 H73 nuclear antigenMA-3 apoptosis-relatedfTlS U96628 2.4 (topoisomerase-inhibitor suppressed) 77 Table II Other genes: Natural killer cells protein 4 M59807 4.4 R TXK tyrosine kinase fT-cell specific) L27071 3.8 X-linked PEST-containing transporter U05321 2. 1 AMP deamninase 2 M91029 2 N FIP2IHYPL huntingtin-interacting protein AF061034 2 ONASE Ihomolog X90392 2.5 N Transcription factor I11 X77366 2 Histone H2A.2 L19779 2.8 Histone H213 AL021807 2.4 Genes with unknown function: 23808 AF038192 2.1 CGI-1 47 AA307912 2.1 N EST W89120 2.8 EST A1026140 EST A218982 2.4 EST W63684 2 aAbbreviations: R, RT-PCR; N, northern hybridization: W, western blotting: Z, zymography 78

Claims (185)

1. A recombinant mammalian fibrosarcoma cell comprising a recombinant expression construct encoding a mammalian p 2 1 gene, wherein p21 is expressed thereby in the fibrosarcoma cell.

2. A recombinant mammalian fibrosarcoma cell comprising a recombinant expression construct encoding a mammalian p21 gene transcriptionally controlled by an inducible heterologous promoter, wherein expression of p21 from the recombinant expression construct is mediated by contacting the recombinant cell with an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter.

3. A recombinant mammalian fibrosarcoma cell according to claims 1 or 2 that is a human HT1080.

4. The recombinant mammalian fibrosarcoma cell of claims 1 or 2, wherein the mammalian p21 gene is a human p21 gene or CDK-binding fragment thereof.

5. A recombinant mammalian fibrosarcoma cell according to claim 2, further comprising a recombinant expression construct encoding a bacterial lactose repressor, wherein transcription thereof is controlled by a mammalian promoter, wherein the recombinant expression construct encoding a mammalian p21 gene comprises a lactose repressor-responsive promoter element and wherein transcription of p21 is controlled by said lactose-repressor responsive promoter element, and wherein expression of p21 from the recombinant expression construct is mediated by contacting the recombinant cell with a lactose repressor-specific inducing agent.

6. The recombinant mammalian fibrosarcoma cell of claim 5, wherein the cell is a human HT1080 fibrosarcoma cell.

7. The recombinant mammalian fibrosarcoma cell of claim 5, wherein the recombinant expression construct encoding a bacterial lactose repressor is 3'SS.

8. The recombinant mammalian fibrosarcoma cell of claim 5, wherein the mammalian p21 gene is a human p21 gene or CDK-binding fragment thereof.

9. The recombinant mammalian fibrosarcoma cell of claim 5, wherein the second expression construct is LNp2 1C3. The recombinant mammalian fibrosarcoma cell of claim 5, wherein the lactose repressor-specific inducing agent is a p-galactoside.

11. The recombinant mammalian fibrosarcoma cell of claim 5, identified by A.T.C.C. Accession No. PTA 1664 (p21-9).

12. A method for identifying a compound that inhibitsCDK inhibitor- mediated modulation of cellular gene expression, the method comprising the steps of: producing expression of a CDK inhibitor in a mammalian cell; assaying the cell in the presence of the compound for changes in expression of cellular genes whose expression is modulated by the CDK inhibitor; and identifying the compound as an inhibitor of CDK inhibitor-mediated modulation of cellular gene expression if expression of the cellular genes of subpart is changed to a lesser extent in the presence of the compound.

13. The method of claim 12, wherein the CDK inhibitor is p16 or p21.

14. The method of Claim 12, wherein the mammalian cell is a cell according to Claim 2, wherein the CDK inhibitor is p21 and whereinp21 expression is produced by contacting the cell with an inducing agent that induces transcription from the inducible promoter or removing an agent that inhibits transcription from the promoter. The method of Claim 12, wherein the mammalian cell is a cell according to Claim 226 wherein the CDK inhibitor is p 16 and wherein p 16 expression is produced by contacting the cell with an inducing agent that induces transcription from the inducible promoter or removing an agent that inhibits transcription from the promoter.

16. The method of claim 12, wherein expression of the cellular gene is repressed by p21.

17. The method of claim 13, wherein expression of the cellular gene is -81 repressed by p16.

18. The method of claim 16, wherein the cellular gene is identified in Table I.

19. The method of claim 14A, wherein the cellular gene is identified in Table The method of claim 12, wherein expression of the cellular gene is induced by p 21

21. The method of claim 13, wherein expression of the cellular gene is induced by p16.

22. The method of claim 20, wherein the cellular gene is identified in Table II.

23. The method of claim 21, wherein the cellular gene is identified in Table

24. The method of claims 12 or 13, wherein expression of the cellular gene is detected using an immunological reagent. The method of claims 12 or 13, wherein expression of the cellular gene is detected by assaying for an activity of the cellular gene product. -82-

26. The method of claims 12 or 13, where expression of the cellular gene is detected by hybridization to a complementary nucleic acid.

27.. A mammalian cell comprising a first recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by. a CDK inhibitor, and a second recombinant expression construct encoding a mammalian CDK inhibitor gene, wherein expression of the CDK inhibitor is experimentally-induced in the mammalian cell thereby.

28. A mammalian cell according to claim 27, wherein the CDK inhibitor is p21 or p16.

29. The mammalian cell of claim 27, wherein the recombinant expression construct encoding a mammalian CDK inhibitor gene is under the transcriptional control of an inducible heterologous promoter,- wherein expression of the CDK inhibitorfrom the recombinant expression construct is mediated by contacting the recombinant cell with an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter. A mammalian cell according to claim 29, wherein the CDK inhibitor is p21 or p16. -83

31. A mammalian cell of claims 27 or 28, wherein the reporter gene encodes firefly luciferase, chloramphenicol acetyltransferase, beta-galactosidase, green fluorescent protein, or alkaline phosphatase.

32. A mammalian cell according to claims 27 or 28, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is repressed by a CDK inhibitor.

33. A mammalian cell according to claim 32 wherein the mammalian gene promoter is a promoter of a mammalian gene identified in Table I.

34. A mammalian cell according to claims 27 or 28, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is induced by a CDK inhibitor. A mammalian cell according to claim 34 wherein the mammalian gene promoter is a promoter of a mammalian gene identified in Table II.

36. A mammalian cell comprising a recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is inhibited by a CDK inhibitor, wherein the promoter is from the gene ORC1, PRC1, XRCC9, CDC2, cyclin B1, AIKI, CENP-A, CENP-F, MAD2, BUBRI, MCAK, HSET, CHL1, thymopoietin a, MPP2, CDC47/MCM7, CDC21/MCM4, DNA ligase 1, DNA polymerase a, Rad54, -84- exonuclease HEX1/RAD2, PLK1, DHFR or citron kinase.

37. A mammalian cell comprising a recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is induced by a CDK inhibitor, wherein the promoter is from the gene serum amyloid A, complement C3, connective tissue growth factor, integrin P-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 66 h' c lysosomal P-galactosidase, or cathepsin B.

38. A method for identifying a compound that inhibits CDK inhibitor- mediated modulation of cellular gene expression, the method comprising the steps of: producing expression of a CDK inhibitor in a mammalian cell according to Claims 27 or 28 in the presence or absence of the compound; assaying the cell for changes in expression of the reporter gene; and identifying the compound as an inhibitor of CDK inhibitor-mediated modulation of cellular gene expression if expression of the reporter gene is changed to a lesser extent in the presence of the compound.

39. The method of Claim 38, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is repressed by p21. The method of Claim 38, wherein the reporter gene is under the 85 transcriptional control of a promoter for a mammalian gene whose expression is E repressed by p16.

41. The method of Claims 39 or 40, wherein the mammalian gene promoter 0 5 is a promoter of a mammalian gene identified in Table I.

42. The method of Claim 38, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is induced by p2 i.

43. The method of Claim 38, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is induced by p16.

44. The method of Claims 42 or 43, wherein the mammalian gene promoter is a promoter of a mammalian gene identified in Table II. The method of claims 38, wherein expression of the reporter gene is detected using an immunological reagent.

46. The method of claims 38, wherein expression of the reporter gene is detected by assaying for an activity of the reporter gene product.

47. The method of claims 38, where expression of the reporter gene is

86- detected by hybridization to a complementary nucleic acid. 48. A method for identifying a compound that inhibits CDK inhibitor- mediated modulation of cellular gene expression, the method comprising the steps of: producing expression ofa CDK inhibitor in a mammalian cell according to Claim 36 in the presence or absence of the compound; assaying the cell for changes in expression of the reporter gene; and identifying the compound as an inhibitor of CDK inhibitor-mediated modulation of cellular gene expression if expression of the reporter gene is changed to a lesser extent in the presence of the compound. 49. The method of claim 48, wherein the CDK inhibitor is p21 or p 16. A method for identifying a compound that inhibits CDK inhibitor- mediated modulation of cellular gene expression, the method comprising the steps of: producing expression of a CDK inhibitor in a mammalian cell according to Claim 37 in the presence or absence of the compound; assaying the cell for changes in expression of the reporter gene; and identifying the compound as an inhibitor of CDK inhibitor-mediated modulation of cellular gene expression if expression of the reporter gene is changed to a lesser extent in the presence of the compound. 51. The method of claim 50, wherein the CDK inhibitor is p21 or p 16. -87- 52. A method for identifying a compound that inhibits senescence in a mammalian cell, the method comprising the steps of: treating the mammalian cell in the presence and absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence; assaying the mammalian cell for repression or induction of genes that are repressed or induced by CDK inhibitor gene expression; and identifying the compound as an inhibitor of senescence if genes that are repressed by the CDK inhibitor are repressed to a lesser extent, or genes that are induced by the CDK inhibitor are induced to a lesser extent, in the presence of the compound than in the absence of the compound. 53. The method of claim 52, wherein the CDK inhibitor is p21 or p16. 54. The method of claim 52, wherein the mammalian cell is assayed for genes that are induced by a CDK inhibitor. The method of claim 54, wherein the CDK inhibitor is p21 or p16. 56. The method of claims 54 or 55, wherein the genes are identified in Table IT. 57. The method of claim 52, wherein the mammalian cell is assayed for genes that are repressed by a CDK inhibitor. -88- 58. The method of claim 43, wherein the CDK inhibitor is p21 or p1 6 59. The method of claims 57 or 58, wherein the genes are identified in Table S I. The method of claims 52 or 53, wherein expression of the cellular gene is detected using an immunological reagent. 61. The method of claims 52 or 53, wherein expression of the cellular gene is detected by assaying for an activity of the cellular gene product. 62. The method of claims 52 or 53, where expression of the cellular gene is detected by hybridization to a complementary nucleic acid. 63. A method for identifying a compound that inhibits senescence in a mammalian cell, the method comprising the steps of: contacting a mammalian cell in the presence or absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence, wherein the cell comprises a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor; assaying the cell for changes in expression of the reporter gene; and identifying the compound as an inhibitor of senescence if expression of -89- the reporter gene is changed to a lesser degree in the presence of the compound than in the absence of the compound. 64. The method of claim 63, wherein the CDK inhibitor is p21 or p16. The method of Claim 63, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is induced by a CDK inhibitor. 66. The method of claim65, wherein the CDK inhibitor is p21 or p16. 67. The method of claims 65 or 66, wherein the mammalian gene promoter is a promoter of a mammalian gene identified in Table II. 68. The method of Claim 63, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is repressed by a CDK inhibitor. 69. The method of claim 68, wherein the CDK inhibitor is p21 or p16. The method of claims 68 or 69, wherein the mammalian gene promoter is a promoter of a mammalian gene identified in Table I. 71. The method of claims 68 or 69, wherein expression of the cellular gene is detected using an immunological reagent. 72. The method ofc!aims 68 or 69, wherein expression of the cellular gene is detected by assaying for an activity of the cellular gene product. 73. The method of claims 68 or 69, where expression of the cellular gene is detected by hybridization to a complementary nucleic acid. 74. A method for identifying a compound that inhibits senescence in a mammalian cell, the method comprising the steps of: contacting a mammalian cell according to Claim 36 in the presence or absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence; assaying the cell for changes in expression of the reporter gene; and identifying the compound as an inhibitor of senescence if expression of the reporter gene is changed to a lesser degree in the presence of the compound than in the absence of the compound. A method for identifying a compound that inhibits senescence in a mammalian cell, the method comprising the steps of: contacting a mammalian cell according to Claim 37 in the presence or absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence; assaying the cell for changes in expression of the reporter gene; and -91- identifying the compound as an inhibitor of senescence if expression of the reporter gene is changed to a lesser degree in the presence of the compound than in the absence of the compound. 76. A method for inhibiting cellular senescence, the method comprising the step of contacting the cell with a compound produced according to the method of claim 12. 77. A method for inhibiting cellular senescence, the method comprising the step of contacting the cell with a compound produced according to the method of claim 38. 78. A method for inhibiting cellular senescence, the method comprising the step of contacting the cell with a compound produced according to the method of claim 48. 79. A method for inhibiting cellular senescence, the method comprising the step of contacting the cell with a compound produced according to the method of claim A method for inhibiting cellular senescence, the method comprising the step of contacting the cell with a compound produced according to the method of claim 52. -92- 81. A method for inhibiting cellular senescence, the method comprising the step of contacting the cell with a compound produced according to the method of claim 63. 82. A method for inhibiting cellular senescence, the method comprising the step of contacting the cell with a compound produced according to the method of claim 74. 83. A method for inhibiting cellular senescence, the method comprising the step of contacting the cell with a compound produced according to the method of claim 84. A method for inhibiting production of disease-associated gene products in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 12. A method for inhibiting production of disease-associated gene products in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 38. 86. A method for inhibiting production of disease-associated gene products in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 48. -93

87. A method for inhibiting production of disease-associated gene products in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim

88. A method for inhibiting production of disease-associated gene products in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 52.

89. A method for inhibiting production of disease-associated gene products in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 63. A method for inhibiting production of disease-associated gene products in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 74.

91. A method for inhibiting production of disease-associated gene products in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim

92. A method for identifying a compound that potentiates the effects of CDK inhibitor mediated modulation of cellular gene expression, the method comprising the steps of: producing expression of a CDK inhibitor in a mammalian cell; -94- assaying the cell in the presence and absence of the compound for changes in expression of cellular genes whose expression is induced or repressed a CDK inhibitor; and identifying the compound as a potentiator of CDK inhibitor-mediated modulation of cellular gene expression if expression of the cellular genes of subpart is induced or repressed to a greater extent in the presence of the compound than in the absence of the compound.

93. The method of claim 92, wherein the CDK inhibitor is p21 or p 16.

94. The method of Claim 92, wherein the mammalian cell is a cell according to Claim 2 wherein p21 is expressed and wherein p21 expression is produced by contacting the cell with an inducing agent that induces transcription from the inducible promoter. The method of Claim 92, wherein the mammalian cell is a cell according to Claim 226 wherein p16 is expressed and wherein p16 expression is produced by contacting the cell with an inducing agent that induces transcription from the inducible promoter.

96. The method of claim 92, wherein expression of the cellular gene is repressed by a CDK inhibitor.

97. The method of claim 92, wherein the CDK inhibitor is p21 or p16.

98. The method of claims 96 or 97, wherein the cellular gene is identified in Table I.

99. The method of claim 92, wherein expression of the cellular gene is induced by a CDK inhibitor.

100. The method of claim 99, wherein the CDK inhibitor is p21 or p16.

101. The method of claims 99 or 100, wherein the cellular gene is identified in Table If.

102. The method of claims 92 or 93, wherein expression of the cellular gene is detected using an immunological reagent.

103. The method of claims 92 or 93, wherein expression of the cellular gene is detected by assaying for an activity of the cellular gene product.

104. The method of claims 92 or 100, where expression of the cellular gene is detected by hybridization to a complementary nucleic acid.

105. The method of claim 92, wherein the CDK inhibitor is produced in the cell to an extent that its effect is less than the maximum effect of the CDK inhibitor expression in the cell. 96-

106. The method of claim 105, wherein the CDK inhibitor is p21 or p16.

107. A method for identifying a compound that potentiates senescence, the method comprising the steps of: contacting a mammalian cell in the presence or absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence, wherein the cell comprises a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor; assaying the cell for changes in expression of the reporter gene; and identifying the compound as a potentiator of senescence if expression of the reporter gene changes to a greater extent in the presence of the compound than in the absence of the compound.

108. The method of claim 107, wherein the CDK inhibitor is p21 or p16.

109. The method of Claim 107, wherein the mammalian cell is a cell Saccording to Claim 2 wherein the CDK inhibitor is p21 and wherein senescence is produced by contacting the cell with an inducing agent that induces p21 transcription from the inducible promoter.

110. The method of Claim 84, wherein the mammalian cell is a cell according to Claim 226 wherein the CDK inhibitor is p16 and wherein senescence is produced by -97- contacting the cell with an inducing agent that induces p16 transcription from the inducible promoter.

111. The method of Claim 107, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is induced by a CDK inhibitor.

112. The method of claim 111, wherein the CDK inhibitor is p21 or p16.

113. The method of claims 111 or 112, wherein the genes are identified in Table II.

114. The method of Claim 107, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is repressed by a CDK inhibitor.

115. The method of claim 114, wherein the CDK inhibitor is p21 or p1 6

116. The method of claims 114 or 115, wherein the genes are identified in Table I.

117. The method of claims 107 or 108, wherein expression of the reporter gene is detected using an immunological reagent. -98-

118. The method of claims 107 or 108, wherein expression of the reporter gene is detected by assaying for an activity of the cellular gene product.

119. The method of claims 107 or 108, where expression of the reporter gene is detected by hybridization to a complementary nucleic acid.

120. A method for identifying a compound that promotes induction of senescence in a mammalian cell, the method comprising the steps of: treating the mammalian cell with an agent or culturing the mammalian cell under conditions that induce senescence in the presence of the compound; assaying the mammalian cell for repression or induction of genes that are repressed or induced by CDK inhibitor gene expression; and identifying compounds that promote induction of senescence if genes that are repressed by the CDK inhibitor are further repressed, or genes that are induced by the CDK inhibitor are further induced, in the presence of the compound.

121. The method of claim 120, wherein the CDK inhibitor is p21 or p 1 6.

122. The method of claim 120, wherein the mammalian cell is assayed for genes that are induced by a CDK inhibitor.

123. The method of claim 122, wherein the CDK inhibitor is p21 or p16. -99-

124. The method of claims 122 or 123, wherein the genes are identified in Table II.

125. The method of claim 120, wherein the mammalian cell is assayed for genes that are repressed by a CDK inhibitor.

126. The method of claim 125, wherein the CDK inhibitor is p21 or p16.

127. The method of claims 125 or 126, wherein the genes are identified in Table I.

128. The method of claims 120 or 121, wherein expression of the cellular gene is detected using an immunological reagent.

129. The method of claims 120 or 121, wherein expression of the cellular gene is detected by assaying for an activity of the cellular gene product.

130. The method of claims 120 or 121, where expression of the cellular gene is detected by hybridization to a complementary nucleic acid.

131. A method for identifying a compound that promotes induction of senescence in a mammalian cell, the method comprising the steps of: contacting a mammalian cell in the presence or absence of the -100- compound with an agent or culturing the mammalian cell under conditions that induce senescence, wherein the cell comprises a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor; assaying the cell for changes in expression of the reporter gene; and identifying compounds that promote induction of senescence if expression of the reporter gene changes to a greater extent in the presence of the compound than in the absence of the compound.

132. The method of claim 131, wherein the CDK inhibitor is p21 or p 16.

133. The method of Claim 131, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is induced by a CDK inhibitor.

134. The method of claim 133, wherein the CDK inhibitor is p21 or p16.

135. The method of claims.133 or 134; wherein the genes are identified in Table II.

136. The method of Claim 131, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is repressed by a CDK inhibitor. -101

137. The method of claim 136, wherein the CDK inhibitor is p21 or p16.

138. The method of claims 136 or 137, wherein the genes are identified in Table I. s

139. The method of claims 131 or 132, wherein expression of the cellular gene is detected using an immunological reagent.

140. The method of claims 131 or 132, wherein expression of the cellular gene is detected by assaying for an activity of the cellular gene product.

141. The method of claims 131 or 132, where expression of the cellular gene is detected by hybridization to a complementary nucleic acid.

142. A method for identifying a compound that promotes induction of senescence in a mammalian cell, the method comprising the steps of: contacting a mammalian cell according to Claim 28 in the presence or absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence; assaying the cell for changes in expression of the reporter gene; and identifying compounds that promote induction of senescence if expression of the reporter gene changes to a greater extent in the presence of the compound than in the absence of the compound. -102-

143. A method for identifying a compound that promotes induction of senescence in a mammalian cell, the method comprising the steps of: contacting a mammalian cell according to Claim 37 in the presence or absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence; assaying the cell for changes in expression of the reporter gene; and identifying compounds that promote induction of senescence if expression of the reporter gene changes to a greater extent in the presence of the compound than in the absence of the compound.

144. A method for promoting senescence in a cell, the method comprising the step of contacting the cell with a compound produced according to the method of claims, 92 or 93.

145. The method of claim 144, wherein the cell is a tumor cell, a hyperplastic cell or a cell that is pathological or disease-causing due to excessive proliferation.

146. A method for promoting senescence in a cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 107 or 108.

147. The method of claim 146, wherein the cell is a tumor cell, a hyperplastic cell or a cell that is pathological or disease-causing due to excessive proliferation. 103

148. A method for promoting senescence in a cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 120 or 121.

149. The method of claim 148, wherein the cell is a tumor cell, a hyperplastic cell or a cell that is pathological or disease-causing due to excessive proliferation.

150. A method for promoting senescence in a cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 131 or 132.

151. The method of claim 150, wherein the cell is a tumor cell, a hyperplastic cell or a cell that is pathological or disease-causing due to excessive proliferation.

152. A method for promoting senescence in a cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 142.

153. The method of claim 152, wherein the cell is a tumor cell, a hyperplastic cell or a cell that is pathological or disease-causing due to excessive proliferation.

154. A method for promoting senescence in a cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 147. -104-

155. The method of claim 154, wherein the cell is a tumor cell, a hyperplastic cell or a cell that is pathological or disease-causing due to excessive proliferation.

156. A compound that inhibits CDK inhibitor modulation of cellular gene expression, wherein the compound is produced by a method having the steps of: inducing expression of a CDK inhibitor in a mammalian cell; assaying the cell in the presence or absence of the compound for changes in expression of cellular genes whose expression is modulated by the CDK inhibitor; and identifying the compound as an inhibitor of CDK inhibitor-mediated modulation of cellular gene expression if expression of the cellular genes of subpart is changed to a lesser extent in the presence of the compound than in the absence of the compound.

157. The method of claim 156, wherein the CDK inhibitor is p21 or p16.

158. A compound that inhibits CDK inhibitor modulation of cellular gene -expression, wherein the compound is produced by a method having the steps of: producing expression ofa CDK inhibitor in a mammalian cell according to Claim 27 in the presence or absence of the compound; assaying the cell for changes in expression of the reporter gene; and identifying the compound as an inhibitor of CDK inhibitor-mediated modulation of cellular gene expression if expression of the reporter gene 105- is changed to a lesser extent in the presence of the compound.

159. The method of claim 158, wherein the CDK inhibitor is p21 or p16.

160. A compound that inhibits senescence in a mammalian cell, wherein the compound is produced by a method having the steps of: treating the mammalian cell in the presence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence; assaying the mammalian cell for repression or induction of genes that are repressed or induced by CDK inhibitor gene expression; and identifying the compound as an inhibitor of senescence if genes that are repressed by the CDK inhibitor are repressed to a lesser extent, or genes that are induced by the CDK inhibitor are induced to a lesser extent, in the presence of the compound.

161. The method of claim 160, wherein the CDK inhibitor is p21 or p16.

162. compound is (a) A compound that inhibits senescence in a mammalian cell, wherein the produced by a method having the steps of: contacting a mammalian cell in the presence or absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence, wherein the cell comprises a reporter gene under the transcriptional control of a promoter for a mammalian gene whose 106- expression is modulated by a CDK inhibitor; assaying the cell for changes in expression of the reporter gene; and identifying the compound as an inhibitor of senescence if expression of the reporter gene is changed to a lesser extent in the presence of the compound.

163. The method of claim162, wherein the CDK inhibitor is p21 or p16.

164. A compound that potentiates senescence in a mammalian cell, wherein the compound is produced by a method having the steps of: producing expression of a CDK inhibitor in a mammalian cell; assaying the cell for changes in expression of cellular genes whose expression is induced or repressed by the CDK inhibitor; and identifying the compound as a potentiator of senescence if expression of the cellular genes of subpart is induced or repressed to a greater extent in the presence of the compound than in the absence of the compound.

165. The method of claim 164, wherein the CDK inhibitor is p21 or p16.

166. A compound that potentiates senescence in a mammalian cell, wherein the compound is produced by a method having the steps of: treating the mammalian cell in the presence of the compound with an agent or culturing the mammalian cell under conditions that induce 107- senescence; assaying the mammalian cell for repression or induction of genes that are repressed or induced by CDK inhibitor gene expression; and identifying the compound as a potentiator of senescence if genes that are repressed by the CDK inhibitor are repressed to a greater extent, or genes that are induced by the CDK inhibito are induced to a greater extent, in the presence of the compound.

167. The method of claim 166, wherein the CDK inhibitor is p21 or p16.

168. A compound that potentiates senescence in a mammalian cell, wherein the compound is produced by a method having the steps of: contacting a mammalian cell in the presence or absence of the compound with an agent or culturing the mammalian cell under conditions that induce senescence, wherein the cell comprises a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK inhibitor; assaying the cell for changes in expression of the reporter gene; and identifying the compound as a potentiator of senescence if expression of the reporter gene changes to a greater extent in the presence of the compound than in the absence of the compound.

169. The method of claim 168, wherein the CDK inhibitor is p21 or p 16 108-

170. A method for producing an anti-apoptotic or mitogenic factor from a mammalian cell, the method comprising the steps of producing CDK inhibitor gene expression in the mammalian cell and culturing the cell in a cell culture medium for a time sufficient to produce the anti-apoptotic or mitogenic factor.

171. The method of claim 170, wherein the mammalian cell is a mammalian cell according to claim 2, wherein the CDK inhibitor is p21 and wherein p21 expression is induced by culturing the mammalian cell in a culture medium containing an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter. 172 The method of claim 170, wherein the mammalian cell is a mammalian cell according to claim 226, wherein the CDK inhibitor is p16 and wherein p16 expression is induced by culturing the mammalian cell in a culture medium containing an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter.

173. A method according to claim 170, wherein the anti-apoptotic or -mitogenic compound produced by the mammalian cell is a compound whose expression is induced by a CDK inhibitor.

174. The method of claim 173, wherein the CDK inhibitor is p21 or p1 6

175. A mammalian cell culture media, conditioned by growth of a mammalian -109- cell that expresses a CDK inhibitor.

176. The mammalian cell culture media claim 175, wherein the CDK inhibitor is p21 orpl6.

177. A mammalian cell culture media according to claim 175, wherein the mammalian cell is a mammalian cell according to claim 2 wherein the CDK inhibitor is p21 and wherein p21 expression is induced by culturing the mammalian cell in a culture medium containing an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter.

178. A mammalian cell culture media according to claim 175, wherein the mammalian cell is a mammalian cell according to claim 226 wherein the CDK inhibitor is p16 and wherein p16 expression is induced by culturing the mammalian cell in a culture medium containing an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter.

179. A method for obtaining a plurality of nucleic acid species enriched for genes involved in cell cycle progression, the method comprising the steps of: inducing expression of a CDK inhibitor in a mammalian cell; obtaining cellular mRNA from a mammalian cell before and after the CDK inhibitor is induced according to step comparing expression of the cellular mRNA obtained from the cell -110- before the CDK inhibitoris induced with expression of cellular mRNA after the CDK inhibitor is induced; and obtaining the plurality of nucleic acid species enriched for genes whose expression is repressed in the cell after CDK inhibitor expression is induced.

180. The method of claim 179, wherein the CDK inhibitor is p21 or pi 16.

181. A method for obtaining a plurality of nucleic acid species enriched for genes that encode secreted proteins with paracrine functions and proteins involved in senescence and age-related diseases, the method comprising the steps of: inducing expression of a CDK inhibitor in a mammalian cell; obtaining cellular mRNA from a mammalian cell before and after the CDK inhibitor is induced; and obtaining the plurality of nucleic acid species enriched for genes whose expression is induced in the cell after CDK inhibitor expression is induced.

182. The method of claim 181, wherein the CDK inhibitor is p21 or p16.

183. A method for identifying a plurality of cellular genes that are markers of cellular senescence, comprising the steps of: inducing expression of a CDK inhibitor in a first population of mammalian cells and quiescence in a second population of mammalian cells; -111- obtaining mRNA from each population of cells; comparing the pattern of gene expression in cells in the first population before and after the CDK inhibitor is induced with the pattern of gene expression in cells in the second population before and after the cells became quiescent; comparing the plurality of genes strongly induced in the CDK inhibitor- induced cells with the plurality of genes strongly induced in quiescent cells; and identifying the genes strongly induced in CDK inhibitor induced cells that are not strongly induced in quiescent cells.

184. The method of claim 183, wherein the CDK inhibitor is p21 or p16.

185. A method for detecting senescence in a mammalian cell, the method comprising the step of detecting expression ofa gene selected from the group consisting of the genes are connective tissue growth factor, serum amyloid A, integrin 13-3, activin A, natural killer cell protein 4, Mac2 binding protein, or tissue transglutaminase.

186. A method for identifying a compound that induces senescence in a mammalian cell, the method comprising the steps of: assaying a mammalian cell in the presence and absence of the compound for expression of a gene whose expression is modulated by a CDK inhibitor; and identifying compounds that induce senescence when expression of a -112- gene that is repressed by the CDK inhibitor is repressed in the cell, or expression of a gene that is induced by the CDK inhibitor is increased in the cell, in the presence of the compound.

187. The method of claim 186, wherein the CDK inhibitor is p21 or p16.

188. The method of Claim 186, wherein the gene is induced by a CDK inhibitor.

189. The method of claim 188, wherein the CDK inhibitor is p21 or p16.

190. The method of claims 188 or 189, wherein the gene is identified in Table

191. The method of Claim 186, wherein the gene is repressed by a CDK inhibitor.

192. The method of claim 191, wherein the CDK inhibitor is p21 or p16.

193. The method of claims 191 or 192, wherein the gene is identified in Table I.

194. The method of claims 186 or 187, wherein expression of the gene is detected using an immunological reagent. -113-

195. The method of claims 186 or 187, wherein expression of the gene is detected by assaying for an activity of the cellular gene product.

196. The method of claims 186 or 187, where expression of the gene is detected by hybridization to a complementary nucleic acid.

197. The method of claim 186, wherein the assay in subpart is performed in the presence of an anticancer drug.

198. The method of claim 186, wherein the mammalian cell comprises an inducible p21 gene, and wherein the assay in subpart is performed in the presence of an amount of an agent that induces p21 expression whereby the extent of p21 induction is insufficient for complete inhibition of genes inhibited by p21.

199. The method of claim 186, wherein the mammalian cell comprises an inducible p16 gene, and wherein the assay in subpart is performed in the presence of an amount of an agent that induces p16 expression whereby the extent of p 16 induction is insufficient for complete inhibition of genes inhibited by p 16.

200. A method for identifying a compound that induces senescence in a mammalian cell, the method comprising the steps of: contacting a mammalian cell with the compound, wherein the cell comprises a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is modulated by a CDK -114- inhibitor; assaying the cell for changes in expression of the reporter gene; and identifying compounds that induce senescence if expression of the reporter gene is reduced when under the transcriptional control of a promoter from a gene repressed by the CDK inhibitor, or expression of the reporter gene is increased when under the transcriptional control of genes that are induced by the CDK inhibitor, when the cell is contacted with the compound.

201. The method of claim 200, wherein the CDK inhibitor is p21 or p16.

202. The method of Claim 200, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is induced by a CDK inhibitor.

203. The method of claim 202, wherein the CDK inhibitor is p21 or p16.

204. The method of claims 202 or 203, wherein the genes are identified in Table II.

205. The method of Claim 200, wherein the reporter gene is under the transcriptional control of a promoter for a mammalian gene whose expression is repressed by a CDK inhibitor. 115-

206. The method of claim 205, wherein the CDK inhibitor is p21 or p16.

207. The method of claims 205 or 206, wherein the genes are identified in Table I.

208. The method of claims 200 or 201, wherein expression of the reporter gene is detected using an immunological reagent.

209. The method of claims 200 or 201, wherein expression of the reporter gene is detected by assaying for an activity of the cellular gene product.

210. The method of claims 200 or 201, where expression of the reporter gene is detected by hybridization to a complementary nucleic acid.

211. A recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is inhibited by a CDK inhibitor.

212. The recombinant expression construct of claim 211, wherein the CDK inhibitor is p21 or p16.

213. A recombinant expression construct according to claims 211 or 212, wherein the promoter is from the gene ORC 1, PRC 1, XRCC9, CDC2, cyclin B 1, AIK1, CENP-A, CENP-F, MAD2, BUBRI, MCAK, HSET, CHLI, thymopoietin a, MPP2, -116- CDC47/MCM7, CDC21/MCM4, DNA ligase 1, DNA polymerase a, Rad54, exonuclease HEX /RAD2, PLK1, DHFR or citron kinase.

214. A recombinant expression construct encoding a reporter gene under the transcriptional control of a promoter for a mammalian gene whose expression is induced by a CDK inhibitor.

215. The recombinant expression construct of claim 214, wherein the CDK inhibitor is p21 or p16.

216. A recombinant expression construct according to claims 214 or 215, wherein the promoter is from the gene serum amyloid A, complement C3, connective tissue growth factor, integrin p-3, activin A, natural killer cell protein 4, prosaposin, Mac2 binding protein, galectin-3, superoxide dismutase 2, granulin/epithelin, p 6 6 sh, lysosomal p-galactosidase, or cathepsin B.

217. A method for inhibiting production of mitogenic or anti-apoptotic compounds in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claims 12 or 13.

218. A method for inhibiting production of mitogenic or anti-apoptotic compounds in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claims 38 or 39. -117-

219. A method for inhibiting production of mitogenic or anti-apoptotic compounds in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claims 48 or 49.

220. A method for inhibiting production of mitogenic or anti-apoptotic compounds in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claims 50 or 51.

221. A method for inhibiting production of mitogenic or anti-apoptotic compounds in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claims 52 or 53.

222. A method for inhibiting production of mitogenic or anti-apoptotic compounds in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claims 63 or 64.

223. A method for inhibiting production of mitogenic or anti-apoptotic compounds in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim 74.

224. A method for inhibiting of production mitogenic or anti-apoptotic compounds in a mammalian cell, the method comprising the step of contacting the cell with a compound produced according to the method of claim -118-

225. A recombinant mammalian fibrosarcoma cell comprising a recombinant expression construct encoding a mammalian p16 gene, wherein p 16 is expressed thereby in the fibrosarcoma cell.

226. A recombinant mammalian fibrosarcoma cell comprising a recombinant expression construct encoding a mammalian p16 gene transcriptionally controlled by an inducible heterologous promoter, wherein expression of p16 from the recombinant expression construct is mediated by contacting the recombinant cell with an inducing agent that induces transcription from the inducible promoter or by removing an agent that inhibits transcription from such promoter.

227. A recombinant mammalian fibrosarcoma cell according to claims 225 or 226 that is a human HT1080.

228. The recombinant mammalian fibrosarcoma cell of claims 225 or 226, wherein the mammalian p16 gene is a human p16 gene

229. A recombinant mammalian fibrosarcoma cell according to claim 226, -further comprising a recombinant expression construct encoding a bacterial lactose repressor, wherein transcription thereof is controlled by a mammalian promoter, wherein the recombinant expression construct encoding a mammalian p16 gene comprises a lactose repressor-responsive promoter element and wherein transcription of p16 is controlled by said lactose-repressor responsive promoter element, and wherein expression ofpl6 from the recombinant expression construct is mediated by contacting 119- the recombinant cell with a lactose repressor-specific inducing agent.

230. The recombinant mammalian fibrosarcoma cell of claim 229, wherein the cell is a human HT1080 fibrosarcoma cell.

231. The recombinant mammalian fibrosarcoma cell of claim 229, wherein the recombinant expression construct encoding a bacterial lactose repressor is 3'SS.

232. The recombinant mammalian fibrosarcoma cell of claim 229, wherein the mammalian p16 gene is a human p16 gene.

233. The recombinant mammalian fibrosarcoma cell of claim 229, wherein the second expression construct is LNpl6RO2.

234. The recombinant mammalian fibrosarcoma cell of claim 229, wherein the lactose repressor-specific inducing agent is a /-galactoside. Dated 3 March 2006 Board of Trustees of the University of Illinois Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON